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Abstract 
Dengue is a significant disease globally. An estimated 50 to 100 million dengue 
infections occur annually, and more are at risk of being infected with 2.5 billion people 
living in dengue endemic countries. Although vector reduction programmes may limit 
dengue virus (DENV) transmission, it has not been carried out at a scale sufficient to 
control the disease globally. A tetravalent dengue vaccine is therefore needed to halt this 
worldwide escalation in disease incidence. Serotype-specific antibodies generated in a 
course of infection are thought to confer lifelong immunity to the same serotype of 
DENV; whereas cross-reactive antibodies are more frequently associated with antibody-
mediated enhancement of infection, leading to more severe disease. Despite the fact that 
antibody-DENV interactions can lead to immunity or immunopathogenesis, the factors 
governing such outcomes of infection have not been well defined.  This has thus led to 
long delays in the development of a safe and effective vaccine. In this thesis, we sought 
to understand the immunity end of the spectrum through early antibody-DENV 
interactions with monocytes (the primary targets of dengue infection) that lead to 
neutralization of the virus, using confocal microscopy. 
A simplified method of labelling DENV with a fluorescent Alexa Fluor dye with minimal 
modification to viral viability was developed in this study and subsequently used to 
visualize the early cellular processes taking place when monocytes encounter antibody-
DENV complexes. Using two human-mouse chimeric antibodies, h3H5 and h4G2, as our 
model for serotype-specific and cross-reactive antibodies, respectively, we observed 
significantly different sub-cellular trafficking characteristics in human monocytes. At the 





DENV, immune complexes with 3µg/ml h3H5 were rapidly internalized through the 
activatory  FcγRI and transported to LAMP-1 positive compartments within 30min, while 
that with 100µg/ml h4G2 bound to both FcγRI and FcγRII but internalization was 
delayed. This delay in internalization appeared to be antibody concentration dependent as 
increasing h3H5 concentration to 100 and 400µg/ml showed similar blockade of uptake. 
These observations were also verified in primary monocyte cultures. 
One possible explanation would be that larger viral aggregates were formed at higher 
antibody concentrations and that inhibited efficient Fc receptor-mediated uptake by the 
monocytes. Using a combination of sucrose gradient to separate the viral aggregates by 
size and dynamic light scattering to estimate their diameter, the data indicates that viral 
aggregates with average diameter of 192nm were formed with 100µg/ml of antibody, 
which is significantly larger than virus only (49.1nm) or Fab only controls (57.7nm).  
Taken collectively, increasing concentrations of antibody result in the formation of 
DENV aggregates of different sizes, which appeared to inhibit internalization. The 
mechanism for this is not through competition for FcR by free and unbound antibody. 
Instead the data suggests that larger viral aggregates may enable antibodies to cross-link 
FcR that are normally expressed at lower density. Lowering the antibody concentration 
allowed for efficient internalization, followed rapidly by trafficking of the immune 
complex to the late endosome. However, at these concentrations, viral replication was 
only prevented with serotype-specific but not cross-reactive antibody.  
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1.1. Dengue background 
The earliest record of illnesses compatible with dengue fever found to date was first 
published in a Chinese ‘encyclopedia of disease symptoms and remedies’ during the Jin 
Dynasty (265-420 AD), and formally edited in 610 AD (Sui Dynasty) and again in 992 
AD (Northern Song Dynasty) [Nobuchi, 1979]. In 1779-80, major epidemics of dengue-
like illness were reported in Asia, Africa and North America [Hirsch, 1883; Howe, 1977; 
Pepper, 1941; Rush, 1789], indicating that dengue virus (DENV) had a wide 
geographical distribution as early as the 18th century. This is likely a consequence of a 
flourishing international sea trade. However, it was not until the World War II in the 
1940s that the first of four DENV serotypes, designated DENV 1 (Hawaii strain) and 2 
(NGC strain) were isolated [Hotta, 1952; Sabin and Schlesinger, 1945]. Two more 
serotypes, DENV 3 and 4, were isolated from patients with a hemorrhagic disease during 
an epidemic in Manila in 1956 [Hammon et al., 1960]. Since then, thousands of DENV 
have been isolated from all parts of the tropics; all fitting into the four serotype 
classification. 
DENV belongs to the family Flaviviridae, which consists of 53 different viruses [Gubler 
et al., 2007]. Among these are yellow fever, Japanese encephalitis, tick-borne 
encephalitis and West Nile viruses. DENV is transmitted by Aedes mosquitoes, mainly 
Aedes aegypti, and infects an estimated 50 million people annually with 2.5 billion more 
people at risk of infection each year in the tropical and sub-tropical regions (Fig.1-1). 
Hence, dengue is the most important mosquito-borne viral disease in the world [WHO, 
2007]. Furthermore, these numbers only represent the tip of the iceberg as many dengue 
infections are asymptomatic or present with non-specific febrile illness [Gubler, 1989b]. 
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Nonetheless, its incidence has increased 30-fold over the past 50 years with increasing 
geographical expansion to new countries [Gubler, 2002; Mackenzie et al., 2004]. 
Unprecedented global population growth and the associated unplanned and uncontrolled 
urbanization, lack of effective mosquito control in dengue endemic areas, decay in public 
health infrastructures in most countries, and increase in air travel which provides the ideal 
mechanism for the transport of dengue between population centres of the world are the 
major contributors to the re-emergence of the disease [Gubler, 1998]. With increased air 
travel and exchange of viruses across borders, most endemic countries now have more 




 Figure 1-1 Countries/areas at risk of dengue transmission.  
Dengue is the most important mosquito-borne viral disease in the world, infecting an estimated 50 million people annually with more 
at risk in countries within the tropical and sub-tropical regions. Figure shows the geographical distribution of countries/areas at risk of 




 Figure 1-2 The change in global distribution of dengue serotypes from 1970 to 2004.  
Increased human travel over the decades led to a wider distribution of dengue viruses 
worldwide and these countries have become hyperendemic with more than 1 serotype 




First records of dengue-like disease outbreaks in the Americas can be traced back to the 
fifteenth century in French West Indies and Panama [Wilson and Chen, 2002]. This 
coincides with the introduction of Aedes aegypti on slave ships arriving from West 
Africa. Since then, the vector has become well established in tropical and temperate areas 
of the Americas [Wilson and Chen, 2002]. 
Aedes aegypti not only transmits DENV, it also serves as an epidemic vector for yellow 
fever virus. In an effort to control yellow fever transmission, the Pan American Health 
Organization (PAHO) launched a large-scale intensive campaign that led to the 
eradication of Aedes aegypti from almost all countries in the Americas by 1960s [Soper, 
1963]. The programme not only controlled yellow fever, it also disrupted the dengue 
transmission cycle. As a result, there was no recorded dengue epidemics from 1946 to 
1963 [Wilson and Chen, 2002].  
The support for vector control programmes waned with the decreased incidence of yellow 
fever [Downs, 1969; Sencer, 1969; Soper, 1969]. Consequently, vector control activities 
declined and dengue re-emerged in 1960s and 1970s as Aedes aegypti start to re-infest 
areas where it was eliminated and subsequently spread to areas where it had never been 
reported (Fig. 1-3) [Gubler, 1989a; Gubler, 1998; Wilson and Chen, 2002]. Dengue 
haemorrhagic fever (DHF) made its first appearance in 1981 when a new strain of dengue 
2 was introduced into Cuba and caused a massive epidemic with a total of 344,203 cases, 
of which, 10,312 were severe and 158 were fatal [Kouri et al., 1986].  Since then, dengue 
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outbreaks continued to occur frequently and DHF has been reported in other parts of the 
Caribbean and Central and South America (Fig. 1-4a and b) [Gubler, 1998]. 
Over a period of 30 years, many countries within the Americas (areas with previous 
dengue, as well as new territories) have become endemic with multiple co-circulating 
dengue serotypes [Gubler, 1998]. This corresponds to the expansion and establishment of 
the Aedes mosquitoes in these areas.  With increased human movement due to trade and 
tourism activities, DENV was moved to new geographic areas by viremic individuals that 
were either pre-symptomatic or who develop subclinical infection [Wilder-Smith and 
Gubler, 2008]. 
It is predicted that global warming will increase the epidemic potential of vector-borne 
transmission of DENV as fewer mosquitoes would be necessary to maintain or spread the 
virus to vulnerable human populations [Patz et al., 1998]. It is possible that as the 
temperature rises, mosquitoes can thrive in regions where it was previously too cold to, 
hence expanding the geographic locations of dengue [Halstead, 2008a]. Increased 
temperature also shorten the development time of mosquitoes, thus more mosquitoes can 
reach sexual maturity earlier and spread the virus [Halstead, 2008a]. Higher ambient 
temperature also shortens the extrinsic incubation time and hence it takes a shorter time 
for the mosquitoes to become infective [Halstead, 2008a]. However, this remains 
controversial as many researchers reasoned that the re-emergence and spread of dengue 
epidemics are direct consequences of urbanization and globalization, which led to 
increased movement of people and trade commodities, combined with inefficient public 




  Figure 1-3 Reinfestation of Aedes aegypti in the Americas post eradication.  
A large scale Aedes aegypti eradication programme launched to control yellow fever 
dramatically decreased the vector throughout most of the Americas by 1970. However as 
the support for the vector control programmes waned over time, Aedes aegypti regained 
the geographical distribution it held before the eradication was initiated and further 









Figure 1-4 Incidences of DF/DHF cases in the Americas.  
(a) Distribution of DHF cases before and after 1981. The Americas enjoyed a period of 
35 to 130 years free from dengue disease prior to 1981. From 1981 to 1997, 24 American 
countries reported laboratory-confirmed DHF cases. (b) Cyclical epidemics were 
observed every 3-5 years after 1981 with increased frequency of DF and DHF cases. 




1.1.2. Southeast Asia 
Multiple DENVs have been known to be transmitted in Southeast Asia for a long time 
(Fig. 1-5) [Halstead, 2006]. There was no large-scale vector programmes against Aedes 
aegypti, unlike in the Americas. However, adoption of effective anti-mosquito hygienic 
practices in some areas of Asia during the colonial era helped to control mosquito 
populations [Halstead, 1965].  
The Second World War changed the epidemiology of dengue in Southeast Asia 
permanently as the destruction of cities changed the landscape and places abandoned the 
colonial system [Halstead, 2006]. Movement of troops during war aided the dispersal of 
the DENVs between population centres of the Asia-Pacific regions and by the end of war, 
most countries in Southeast Asia were hyperendemic and epidemic DHF emerged a few 
years later [Gubler, 1997].  Urbanization happened quickly after the war as millions of 
people moved into cities looking for jobs, which led to hurried but unplanned growth of 
urban centres, and hence poor housing, water supply and sewerage system [Ooi and 
Gubler, 2008]. As such, people tend to store water in households, and together with the 
abandoned war equipment and rubbish, these became ideal mosquito breeding sites and 
high density of susceptible human hosts in the cities provided ideal conditions for virus 
propagation [Ooi and Gubler, 2009a]. Thus, the geographic distribution of the viruses and 
vectors expanded, and the densities of Aedes aegypti increased, making many countries in 




Dengue soon emerged as the leading health burden in Southeast Asia. In 1954, 
Philippines recorded its first DHF outbreak and a second outbreak 2 years after in 1956 
[Gubler, 1997]. Since then, DHF cases have been reported yearly [Halstead, 1980]. 
Thailand also had similar dengue history as the Philippines with DHF/DSS (dengue 
shock syndrome) documented as early as 1950s in Bangkok [Halstead, 1980; Halstead 
and Yamarat, 1965]. Vietnam, Indonesia, Cambodia, Sri Lanka, Malaysia and Singapore, 












Figure 1-5 Dengue in Southeast Asia 
(a) Distribution of countries in South and Southeast Asia with records of mosquito-borne 
hemorrhagic fever outbreaks between 1950 and 1964. Adapted from Yale J Biol Med 
37(6): 434-454, 1965. (b) Incidence rate of dengue in Southeast Asia, 2005. Adapted 




 1.1.3. Singapore 
DHF first appeared in Singapore in the 1960s and quickly became a major cause of 
childhood death [Ooi et al., 2006].  A Vector Control Unit was set up in 1966 in response 
to dengue and after a series of entomologic surveys [Chan et al., 1971a; Chan et al., 
1971b; Chan et al., 1971c; Chan et al., 1971d; Ho et al., 1971] and a pilot project was 
started to control the Aedes vectors in an area with high incidence of DHF [Chan, 1967], 
and a vector control system based on entomologic surveillance and larval source 
reduction was launched in 1968 [Chan, 1985; Chan et al., 1977]. In 1966, DHF was made 
a notifiable disease and in 1977, DF also became a notifiable disease [Chan, 1985].  
Since the implementation of the vector control programme, the premises index fell 
sharply from 16% and was maintained at approximately 2% till present day (Fig. 1-6a) 
[Chan, 1967]. As with the reduction of vectors, the number of cases of dengue infections 
dropped and Singapore enjoyed a 15-yr period of low dengue incidences [Ooi et al., 
2006]. However, despite having a successful vector control programme in place, dengue 
incidences surged in the 1990s and the overt (symptomatic) attack rates were several 
folds higher than in the 1960s (Fig. 1-6a) [Ooi et al., 2006]. 
Multiple factors appear to be associated with the re-emergence of dengue in Singapore 
[Ooi et al., 2006]: (1) Lowered herd immunity. Reduced dengue transmission in the 
1970s and 1980s resulted in lowered herd immunity to DENV [Egger et al., 2008; Goh, 
1995]. Low levels of population immunity provided an ideal condition for dengue 
transmission despite low Aedes mosquito density. (2) Transmission outside the home. A 
seroprevalence study on 1,068 children ≤ 15 years of age indicated a shift of dengue 
infection away from home [Ooi et al., 2001]. School-age children were 9 times more 
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likely to have antibodies to dengue than preschool children [Ooi et al., 2001]. Preschool 
children spent most of their time at home or at pre-school care centres whereas school-
age children have formal half-day education in schools followed by extra-curriculum 
activities, hence spend more time outside of home. This suggested that the risk of 
acquiring dengue was higher when a person spent more time away from home [Ooi et al., 
2001]. This was supported by the lower premises index in residences compared to non-
residences in 1997 where schools (27.0%), construction sites (8.3%), factories (7.8%) and 
vacant properties (14.6%), had much higher premises indexes than residential properties 
(2.1% in landed premises and 0.6% in apartments) [Tan, 1997]. (3) Dengue in adults. The 
proportion of patients ≤ 15 years of age had been on the decline while the proportion of 
patients ≥ 25 years of age had been on the rise (Fig. 1-6b). Dengue infections in adults 
tend to be more clinically overt than in children thereby contributing to the increase in 
overall incidence of dengue [Ooi et al., 2003; Seet et al., 2005]. (4) Shift in surveillance 
emphasis. Over time, the vector control programme evolved to emphasize on early case 
detection and warning system to identify active virus transmission areas, rather than 
active vector surveillance and elimination [Ooi et al., 2006]. The passive vector 
surveillance was ineffective at stopping virus transmission, especially in people with 
subclinical or mild undifferentiated fever, to the uninfected mosquitoes. 
Countries embarking on Aedes control programmes may face similar epidemiological 
problems as those encountered by Singapore [Ooi et al., 2006]. Hence an effective 
tetravalent vaccine is the only sustainable solution for dengue. However, until a large-
scale immunization program for dengue becomes available, a community-based 
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integrated control of Aedes aegypti remains the key to prevention and control of DF/DHF 









Figure 1-6 Dengue situation in Singapore. (a) Annual incidences of DF and DHF, and 
the premises index, in Singapore between 1966 and 2005. Since the implementation of 
vector control programme in 1968, the premises index fell dramatically and was 
maintained at about 2% to 2005. DF/DHF cases also plummeted with the reduced 
premises index until their resurgence in 1990. (b) Proportion of dengue patients below 15 
years of age is on the decline while the proportion of patients aged 25 years and above 
are on the rise. Adapted from Emerg Infect Dis 12(6): 887-893, 2006. 
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1.2. Disease and disease management 
Dengue infections are mostly undetected or can present as a self-limiting febrile illness 
(dengue fever, DF), which in some cases develop into more severe forms of the disease: 
dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Figure 1-7 summarizes 
the typical manifestations of dengue infection (a) and spectrum of DHF (b). 
1.2.1. Dengue fever 
Clinical presentations of DF often depend on the age of the patients. While dengue 
infection in infants and young children may present as undifferentiated febrile disease 
accompanied by maculopapular rash or mild DF, older children and adults may 
experience sudden onset of high fever, severe headache, retro-orbital pain, myalgia and 
arthralgia, nausea and vomiting, and rash (Fig. 1-7a) [George and Lum, 1997]. 
Leukopenia and thrombocytopenia may also be observed [George and Lum, 1997]. 
Recovery is often accompanied with fatigue and depression, especially in adults 
[Halstead et al., 2007]. 
1.2.2. Dengue haemorrhagic fever/Dengue shock syndrome 
The 1997 World Health Organization (WHO) guidelines describe DHF as being 
characterized by fever lasting 2-7 days, plasma leakage, hemorrhagic tendency and 
thrombocytopenia (Fig. 1-7a). Patients may experience similar symptoms as DF with the 
addition of hemorrhagic phenomena, usually indicative by positive tourniquet test, easy 
bruising and bleeding at venepuncture sites (Fig. 1-7b). The critical stage of the disease 
typically occurs at the end of the febrile phase when the temperature declines rapidly, and 
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plasma leakage and hemoconcentration can be observed. The patient, if not properly 
managed, can quickly progress into shock (DSS) and be in danger of death. 
In addition to the DHF symptoms, a DSS patient could appear restless, have cold clammy 
skin, weak but rapid pulse and narrow pulse pressure (< 20mmHg) [WHO, 1997]. The 
duration of shock is usually short, lasting 12 to 24 hours, during which the patient 
typically dies or recovers rapidly after appropriate volume replacement therapy [WHO, 





Figure 1-7 Range of dengue disease.  
(a) Dengue infections can have a wide range of clinical manifestations as shown in the 
generalized time course of events associated with DF, DHF and DSS. (b) WHO 
guidelines require each of the four criteria to be met for a diagnosis of DHF. The DHF 
patient can be further categorized to different grades (I-IV) if the corresponding criteria 




1.2.3. Current treatment/dengue control 
Asymptomatic infections and undifferentiated febrile illnesses are the most common 
outcomes of DENV infection in children and can represent more than 50% of cases 
[Burke et al., 1988; Endy et al., 2002]; while DENV infection in adults are more likely to 
be symptomatic [DeTulleo and Kirchhausen, 1998; Seet et al., 2005]. DF is frequently 
self-limiting although it can be incapacitating. Currently, there is no vaccine or specific 
therapy for dengue and all treatment is based on assessment by medical practitioner, 
usually symptomatic and supportive. Severe disease (i.e., DHF or DSS) is rare but may 
be fatal. Without proper, timely treatment, case fatality can exceed 30% in those with 
severe disease; however, with intensive supportive fluid replacement therapy, case 
fatality can be reduced to <1% [WHO, 2009]. Maintenance of the circulating fluid 
volume and hemodynamic status is the central feature of severe case management.  
Without an effective vaccine or anti-viral drug against DENV, the only way to control the 
disease is to limit the exposure of susceptible people to the vectors. Many vector control 
approaches are employed. These include the use of different larvicide, adulticide, 
insecticide-treated materials and genetic strategies to reduce or block viral transmission 
by mosquitoes. One potentially interesting and useful method is the use of Wolbachia, an 
endosymbiotic bacterium, to deliver disease-resistance genes into mosquitoes, thereby 
making them refractory to the human pathogens they transmit. Recently, two groups 
independently demonstrated that introduction of Wolbachia into Aedes aegypti directly 
inhibits DENV from infecting the mosquito and this may be due to the priming of 
mosquito innate immune response and competition for the limited cellular resources 
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[Bian et al., 2010; Moreira et al., 2009]. This may serve as an eco-friendly option to 
human pathogen disease control. 
1.2.4. Vaccine development and progress 
With dengue re-emerging and emerging in more than 100 countries, causing a burden to 
the economy and claiming lives [Halstead, 2008b], a dengue vaccine is urgently needed. 
Experiments to produce attenuated DENV as vaccines started way back in the early 
twentieth century, where Sabin and Schlesinger reported that several passages of DENV 
in mice changed the virus markedly that it can be used as vaccine to produce immunity 
against dengue [Sabin and Schlesinger, 1945].  
Now at the beginning of the 21st century, a pipeline of vaccine candidates does exist. The 
leading candidate vaccine in clinical trials at present is the ChimeriVax dengue vaccine 
(Sanofi Pasteur, Lyon, France). This live attenuated vaccine (LAV) uses the yellow fever 
17D live attenuated vaccine strain as its genetic backbone with the yellow fever envelope 
(E) and pre-membrane (prM) genes replaced with those from each of the 4 DENV 
serotypes. LAVs most closely mimic a natural infection and thus are expected to induce 
durable cellular and humoral immune responses. In order to be successful, they have to 
be adequately attenuated yet maintaining high immunogenicity.  The viruses must be able 
to replicate well to evoke an immune response but sufficiently restricted in systemic 
replication so that no transmission of the viruses by mosquitoes can occur. Importantly, 
the attenuation has to be stable and should not revert to wild type or other virulent forms. 
Antibody responses to the 4 components in the tetravalent formulation should not 
interfere with each other as that could result in preferential antibody responses to the 
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better replicating components, leading to disease susceptibility [Blaney et al., 2006; 
Blaney et al., 2005]. Unfortunately, these issues cannot be assessed accurately before 
clinical trials due to the lack of a good animal model that reproduce the disease in human 
beings. Nonetheless, these Sanofi chimeric viruses have been shown to be attenuated, 
safe in non-human primates and phases I and II clinical trials, and elicit antibodies only to 
dengue [McGee et al., 2008; Monath, 2007]. Other chimeric LAVs in clinical trials 
include one that uses PDK-53 DENV 2 Mahidol vaccine candidate and another that uses 
DENV-4 attenuated by 30-nucleotide deletion of the 3’ untranslated region as the genetic 
backbone, with the E and prM genes replaced by that from the other DENVs [Blaney et 
al., 2008; Blaney et al., 2007; Durbin et al., 2006; Durbin et al., 2005; Huang et al., 2003; 
Rabablert et al., 2007].  
Besides the LAVs, other vaccines in preclinical stages of development include subunit, 
inactivated, DNA and vectored vaccines. Whole inactivated vaccines would have an 
advantage over LAVs as it is impossible for the inactivated viruses to revert back to a 
more pathogenic phenotype, thus making them safe for the immunocompromised. It 
might be also be easier to attain a balanced antibody response against all 4 serotypes. 
However, as they are also less likely to induce a robust and durable immune response, 
multiple dosing or development of potent adjuvants would be required. These would 
make the vaccines expensive and thus a less attractive option. A list of current vaccine 
candidates is shown in Table 1-1.  
As the pathogenic mechanism of DF/DHF remains incompletely understood, especially 
with the possibility that cross-reacting antibodies could enhance DENV infection 














Different approaches taken by various institutes and companies to develop a dengue vaccine. The list above shows the progress of the 
candidate vaccines. Adapted from Lancet Infect Dis 9(11): 678-687, 2009. 
  
Table 1-1 Current ongoing vaccine developments.  
1.3. Life cycle of DENV 
1.3.1. Structure/genome of DENV 
DENV is an enveloped, positive strand RNA virus, with a diameter of approximately 
50nm. Its structure consists of an external icosahedral scaffold of 90 envelope 
glycoprotein (E) dimers protecting the nucleocapsid shell, which contains the 
approximately 10.7 kb RNA genome (Fig. 1-8a) [Kuhn et al., 2002]. The genome 
translates into a large polyprotein encoding the three structural proteins (capsid, 
envelope, pre-membrane/membrane) and 7 non-structural (NS) proteins (NS1, NS2A, 
NS2B, NS3, NS4A, NS4B, NS5), that will be co- and post-translationally cleaved by 
cellular and viral proteases [Lindenbach et al., 2005; Pastorino et al., 2010]. Figure 1-8b 








Figure 1-8 Structure and proteome of DENV.  
(a) Structure of whole virus showing each monomer of the E protein with domains I, II 
and III in red, yellow and blue respectively. (b) Flavivirus genome and polyprotein 
organization. The genome is translated into a single polyprotein which is co- and post-
translationally cleaved by cellular and viral proteases to give 3 structural and 7 non-
structural proteins with different functions. Adapted from Cell 108(5): 717-725, 2002 and 




1.3.2. Entry and exit of DENV  
Much of the knowledge on the mechanism of flavivirus entry into cells was built on work 
done by Gollins and Porterfield with West Nile virus (WNV) on a murine macrophage-
like cell line, P388D1 [Gollins and Porterfield, 1985; Gollins and Porterfield, 1986a; 
Gollins and Porterfield, 1986b; Kimura et al., 1986]. The virus first attaches itself to the 
host cell via its attachment receptor and gets internalized through receptor-mediated 
endocytosis using the same or another cellular receptor [Chu and Ng, 2004; Lindenbach 
et al., 2005]. Once in the endosomes, the acidic environment triggers major conformation 
changes in the E proteins, resulting in the fusion of viral membrane with the endosomal 
membrane. The nucleocapsid containing the viral genome then exits the endosome into 
the cytoplasm where viral replication follows. Newly formed, immature viral particles, 
bud into the endoplasmic reticulum, travel through the trans-Golgi network and before 
release from the cell by exocytosis, the prM protein is cleaved by host furin and the E 
proteins are rearranged into homo-dimers to become mature virion (refer to Fig. 1-9). 
Many molecules have been implicated in DENV entry process; however, none was 
confirmed to be the cellular receptor for the virus (Table 1-2). Among them are putative 
attachment/cellular receptors such as dendritic cell-specific intercellular adhesion 
molecule (DC-SIGN, CD209), mannose receptor, heparin-sulphate, human monocyte-
derived macrophage membrane proteins of the following molecular weights:  27, 45, 67, 
87kDa, heat shock proteins 70 and 90, CLEC5A and CD14-linked molecule [Cabrera-
Hernandez and Smtih, 2005; Chen et al., 2008; Lindenbach et al., 2005; Miller et al., 
2008; Moreno-Altamirano et al., 2002].  
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The primary targets of DENV infection in humans are the cells of mononuclear 
phagocytic lineage including monocytes, macrophages and dendritic cells (DCs) 
[Blackley et al., 2007; Halstead et al., 1977; Kou et al., 2008; Marovich et al., 2001; 
Tassaneetrithep et al., 2003; Wu et al., 2000], although B cells, T cells, endothelial cells, 
hepatocytes, and neuronal cells have also been reported to be permissive to DENV 
[Clyde et al., 2006]. However, most of the studies on viral entry have been conducted on 
cell lines of non-human origin or not from a mononuclear phagocytic lineage (e.g. 
P338D1, murine macrophage-like cell line, Vero, African green monkey kidney epithelial 
cell line). Hence, while these studies have provided valuable information on the 
replication life cycle of flaviviruses, the in vivo relevance pertaining to human beings in 




 Figure 1-9 Replication lifecycle of Flavivirus.  
The virus first enters the cell through receptor-mediated endocytosis and the acidic 
environment in the endosomes trigger major conformational change in the E proteins, 
resulting in fusion of viral membrane with endosomal membrane, hence the release of 
RNA genome into cytoplasm where replication begins. Virus assembly happens in the 
ER and the immature virion is then transported through the secretory pathway. The prM 
is cleaved by furin just before budding of the mature virion. Adapted from Antiviral Res 














Table 1-2 Principle host factors in dengue.  
 
Many host proteins have been identified to play a role in flavivirus infection. The above table gives a summary of the host proteins, 
their known cellular functions and their possible roles in viral infection/replication. Adapted from Antiviral Res, 2010. 
  
1.4. Role of host immune response in dengue 
1.4.1. T cells 
Findings from key epidemiological studies indicated that secondary infections of a 
different serotype that is different from the primary infection in dengue-immune patients 
often lead to more severe disease [Guzman et al., 2000; Sangkawibha et al., 1984]. A 
possible explanation offered for the more severe disease outcome is the original antigenic 
sin of the T cells [Mongkolsapaya et al., 2003]. Memory cells have a lower threshold for 
activation compared to naive cells, hence, cross-reacting memory T cells from the 
primary infection may be rapidly mobilized during the course of a secondary infection 
[Veiga-Fernandes et al., 2000]. However, as they may be of lower affinity for the 
secondary challenge antigen, they are less effective at clearing the secondary infection 
[Mongkolsapaya et al., 2006]. They may instead promote immunopathology with 
increased secretion of proinflammatory cytokines, leading to a more severe disease, but 
die through apoptosis before clearing the infection [Dong et al., 2007; Mongkolsapaya et 
al., 2006]. 
1.4.2. ADE 
The more widely studied model to explain the association between secondary infection 
and severe dengue is antibody-dependent enhancement (ADE) of DENV infection. Pre-
existing antibodies to a specific antigen have always been thought to be beneficial in 
clearing an infection. This forms the basis of vaccination.  However, in the case of 
dengue, presence of heterotypic antibodies during a secondary infection different from 
previous encounter or waning levels of maternally transferred anti-dengue antibodies in 
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infants born to dengue-immune mothers have also been associated with more severe 
disease [Halstead and O'Rourke, 1977; Kliks et al., 1988; Simmons et al., 2007]. These 
observations provided indirect but strong support for ADE. In this hypothesis, antibodies 
generated from a previous infection may not neutralize a heterologous DENV serotype in 
a secondary infection. Instead, they enhance viral infection by targeting the virus to Fc 
receptor-bearing cells through the Fc portion of the antibody, thus bringing the virus 
closer to the cell membrane where it can be internalized through Fc receptor-mediated 
phagocytosis. As the antibody is non-neutralizing, it is incapable of stopping viral 
replication, thus leading to increased viral burden and a more severe disease. Kliks et al 
further tested pre-infection serum specimens collected during a prospective study of 
dengue infections among school children in Bangkok for their ability to enhance DENV 2 
growth in human monocytes in vitro and showed that greater enhancement of virus 
growth correlated with symptomatic disease outcome in natural secondary infection 
[Kliks et al., 1989], hence providing direct evidence that ADE in monocytes is central to 
pathogenesis of DHF. 
A recent prospective, nested, case-control study of dengue in infants in Philippines, 
however, showed that infants exhibit a full range of disease severity after primary 
infections and did not find any association between enhancing antibodies and the 
development of DHF in the infants [Libraty et al., 2009]. This study even suggested that 
rethinking or refinement of the current ADE pathogenesis model for infant DHF is 
necessary and should stimulate new directions of research into mechanisms responsible 
for the development of DHF. However, this difference in the ADE observations may be 
due to differences DENV serotypes.  Whereas the studies by Kliks et al (1988) and 
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Simmons et al (2007) involved DENV 2, DENV 3 was the predominant virus in the study 
by Librarty et al (2009).  Epidemiological observations have previously suggested that 
DENV 2 and 4 cause more symptomatic disease in secondary infection compared to 
DENV 1 and 3 [Henchal et al., 1982]. 
1.4.3. Others risk factors of disease severity? 
It is also possible that both theories can work in conjunction in a secondary infection to 
produce the increased viral load and heightened immune response that led to 
pathogenesis of DHF/DSS. Beside these two well-received theories used to explain the 
more severe disease experienced in certain individuals, recently more studies have 
revealed many other factors that might influence the disease outcome. These include the 
genetic background of an individual (e.g. race, HLA polymorphism and G6PD 
deficiency), virus strain differences, levels of virus circulating in individual during acute 
phase and nutritional status of the infected individual can all play a role in affecting the 
severity of the infection [Chao et al., 2008; de la et al., 2007; Diamond et al., 2000; 
Maron et al., 2010; Stephens, 2010; Thisyakorn and Nimmannitya, 1993; Vaughn et al., 
2000]. 
1.4.4. Antibody neutralization of DENV 
The above review of the current state of knowledge of dengue vaccine development 
underscores the need for mechanistic studies into the molecular basis for virus 
neutralization. Antibodies generated against DENV are protective but are serotype-
specific. Individuals with previous dengue infection are protected against re-infection 
with the same serotype and the anti-dengue antibodies can be detected in the serum even 
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after several decades post infection [Imrie et al., 2007; Russell et al., 1967; Sabin, 1952]. 
Homotypic immunity is thought to be lifelong with a brief period of cross-protection. 
Hence it is important to understand the mechanistic difference between neutralization by 
a homotypic antibody and a cross-reacting antibody, and steer the immune system away 
from producing cross-reacting antibodies. 
Antibody-mediated neutralization of animal viruses is generally thought to occur by a 
‘multi-hit’ mechanism. In this model, it is postulated that virus inactivation is a function 
of the number of antibodies bound to it [Della-Porta and Westaway, 1978; Pierson and 
Diamond, 2008; Pierson et al., 2008].  Neutralization requires the engagement of the 
virion by antibody with a stoichiometry that exceeds a particular threshold. 
Concentrations of antibody that falls below this threshold or antibodies that can never 
reach this threshold, even at maximal binding, will enhance infection in vitro in Fc 
receptor bearing cells. Since all neutralizing antibodies can promote ADE in vitro at sub-
neutralizing concentrations, it is likely that DENV neutralization follows the ‘multi-hit’ 
model. Indeed, this has been demonstrated with the neutralization of DENV 2 by E 
domain III specific antibody [Gromowski et al., 2008]. 
Many potent neutralizing monoclonal antibodies (mab) against flaviviruses have been 
mapped to the lateral ridge of E domain III (e.g. 3H5: DENV 2 specific, E16: WNV) 
[Oliphant et al., 2005; Sukupolvi-Petty et al., 2007]. However, these are murine 
antibodies. Studies of human dengue immune sera demonstrated that E domain III 
antibodies are present, but in low percentages and make only a minor contribution to the 
total neutralizing capacity of human immune sera [Wahala et al., 2009]. Another study in 
Taiwan revealed that antibodies to DENV during a natural course of infection are 
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predominantly cross-reactive and recognized epitopes containing residues at the fusion 
loop of E domain II [Lai et al., 2008]. While an interrogation of the memory B cells from 
7 individuals with previous DENV infection showed that 60% of the antibodies was 
directed towards prM and the other 40% towards E [Dejnirattisai et al., 2010]. None of 
the anti-prM antibodies showed high neutralization in this study, but can instead render 
non-infectious immature or partially mature DENV infectious in Fc receptor-bearing 
cells. These suggest that human antibody repertoire against DENV may be directed 
towards the less neutralizing, more cross-reactive, but immunodominant epitope 
involving the highly conserved fusion loop residues at domain II and prM, away from the 
more potent type-specific neutralizing epitope at domain III. Eliminating or altering 
specific DI/DII and prM epitopes may be a way to redirect antibody responses toward the 
more protective neutralizing epitopes in DIII. 
1.4.5. Monocytes/Macrophages 
To mediate viral clearance, the Fc portion of the antibody-bound DENV immune 
complexes presumably needs to interact with its Fc receptors (e.g. Immunoglobulin G, 
IgG, interacts with Fc gamma receptors, FcγR). FcγRs comprise of multigene family of 
integral membrane glycoproteins that upon aggregation by complexed IgG, exhibit 
complex activation or inhibitory effects on cell function [Nimmerjahn and Ravetch, 
2008]. Two activatory FcγRs are of particular concern in mediating immune complex 
clearance: FcγRI (CD64) and FcγRIIa (CD32). FcγRI has high affinity for monomeric 
and complexed IgG and is found exclusively on antigen-presenting 
monocytes/macrophages and dendritic cells. FcγRIIa preferentially binds multimeric IgG 
with at least 100 fold lower affinity than FcγRI, and is more broadly distributed among a 
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variety of myelogeneous cell types. FcγRI needs to associate with γ-chain subunits that 
consist of immunoreceptor tyrosine-based activation motif (ITAM) for signaling whereas 
FcγRIIa has its own ITAM constitutively expressed in the cytoplasmic tail.  
Monocytes/macrophages bear both FcγRI and FcγRIIa and are the main mediators of 
immune clearance. Macrophages are the first line of defence as they coat and monitor the 
main body compartments. Monocytes circulate in the bloodstream and extravasate into 
tissue to develop into macrophages or dendritic cells, in absence or presence of tissue 
damage or infection, as part of their maturation process or part of an innate immune 
response. Monocytes may also respond to pathogens they encounter while still in the 
circulatory system. As sentinels of the immune system, they may encounter the virus 
early and control viral entry into its target organ(s). However, the situation is made 
complicated as they are also believed to be the primary sites of DENV replication 
[Halstead, 1988; Kou et al., 2008]. Thus, it is important to understand their contribution 
to pathogenesis as well as viral clearance. 
Both FcRs have been shown to play a prominent role in mediating neutralization and 
enhancement of DENV infection [Kou et al., 2008; Rodrigo et al., 2009; Rodrigo et al., 
2006; Schlesinger and Chapman, 1999]. Kou et al had an interesting finding that blocking 
of either FcγRI or FcγRIIa on primary monocytes isolated from dengue-naive donors led 
to approximately 40-60% reduction of ADE of dengue infection, while blocking both Fc 
receptors had no significant additive effect. On the other hand, Rodrigo et al reported that 
FcγRIIa is more efficient than FcγRI in enhancing dengue infection in COS cells 
transiently transfected with either FcγRI or FcγRIIa. In this study, mutations of FcγRIIa 
ITAM that abolish its signaling competency impaired phagocytosis, but unlike with 
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signaling-incompetent FcγRI (γ-chain ITAM mutants), immune enhancement appeared to 
be unaffected. Ligand-clustered FcγRs are known to concentrate in cell membrane 
regions rich in signaling molecules and potential virus receptor engagement sites. It is 
thus possible that FcγRIIa, which preferentially binds immune complexes and exhibit a 
high dissociation rate, is better equipped than FcγRI to utilize the alternative signaling 
pathways and entry mechanisms made available by relocation to such sites where weakly 
bound immune complexes might be more easily transferred to favorable entry pathways. 
Because of their relative affinities to the two FcγRs, different subclasses of IgG also 
modulate the neutralization of DENV in a different manner [Rodrigo et al., 2009]. 
There are also fundamental differences in the intracellular signaling pathways, receptor 
trafficking and antigen processing/presentation stimulated by the FcγRI and FcγRIIa [Dai 
et al., 2009] that can  possibly lead to the differential neutralization/enhancement of 
dengue infection. The two FcγRs utilizes different phospholipases for activation: FcγRI 
uses phospholipase D1 and FcγRIIa uses phopholipase Cγ1.  Immune complexes 
internalized by FcγRI traffic to MIIC compartments (HLA-DM and LAMP-1 positive) 
for processing whereas FcγRIIa traffics to compartments negative for HLA-DM and 
LAMP-1 at equivalent time period, suggesting that they do not traffic to MIIC. It is also 
noted that FcγRI activation elicits the production of higher levels of pro-inflammatory 
cytokines, eg. TNF-α, IL-8, IL-6, IFN-γ, G-CSF and MIP-1β, which suggests that FcγRI 




1.5. Discovery and use of fluorescent proteins in research 
1.5.1. Discovery of GFP: short story of Aequorin, O Shimomura 
In 1960, Osamu Shimomura left Japan with a Fulbright Fellowship to embark on his 
journey to understand the photophysics involved in Aequorean bioluminescence in the 
laboratory of Prof. Frank Johnson at Princeton University, little knowing that this piece 
of work which took more than twenty years of dedication, would transform into one of 
the most useful tools in modern biology and medicine. He successfully isolated aequorin 
and its companion protein, a fluorescent protein that absorbs the blue light emitted by 
aequorin (lmax = 470 nm) through radiationless (Förster-type) energy transfer, and 
fluoresces green (lmax = 509 nm), from the luminous jellyfish Aequorea.  This protein is 
later called green fluorescent protein (GFP). He also managed to solve the chromophore 
structure of GFP. And it was this effort that won him the Nobel Prize in Chemistry for 
2008, which he shares with Martin Chalfie and Roger Tsien, who first demonstrated that 
it is possible to replace the original protein with GFP-fusion protein, thereby showing 
where in the cell the protein resided in C. elegans and Drosophila oocytes, and expanded 
the colour palette of fluorescent proteins by mutation, respectively [Chalfie et al., 1994; 
Heim et al., 1994; Wang and Hazelrigg, 1994; Zimmer, 2009]. 
1.5.2. From GFP to rainbow coloured fruit proteins 
In the same year Chalfie reported the work on GFP-fusion proteins, Roger Tsien reported 
that the autocatalytic chromophore formation in GFP was oxygen dependent and 
proposed the biosynthetic pathway for chromophore formation [Heim et al., 1994]. He 
also described the creation of the first wavelength mutation of GFP and proposed the 
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possibility of utilizing fluorescence energy transfer (FRET) measurements between GFP 
and its mutants, such as the newly created blue fluorescent protein (BFP = a Y66H GFP 
mutant) [Heim et al., 1994]. And since then, the race has been on to produce better and 
brighter fluorescent proteins to fill in every gap in the different spectral classes [Shaner et 
al., 2007]. From a single green fluorescent protein in the 1970s, the colour palette has 
expanded to rainbow colours of mFruit proteins (Fig. 1-10) and beyond. The search for 
new fluorescent proteins is an endless quest as researchers look at isolating new 
fluorescent proteins from marine animals or by mutating existing proteins to derive at 
new proteins with improved properties such as brightness, photostability and Stokes shift. 
A new generation of fluorophores, the Alexa Fluor dyes, are synthesized by Molecular 
Probes, through the sulfonation of coumarin, rhodamine, xanthene (such as fluorescein), 
and cyanine dyes. Sulfonation makes Alexa Fluor dyes negatively charged and 
hydrophilic. Alexa Fluor dyes are generally more stable, brighter, and less pH-sensitive 
than common dyes (e.g. fluorescein, rhodamine) of comparable excitation and emission 
[Panchuk-Voloshina et al., 1999], and to some extent the newer cyanine series [Berlier et 




 Figure 1-10 mFruit fluorescent proteins derived from mRFP or somatic 




1.5.3. Fluorescent proteins in research  
Fluorescent proteins have gained increasing popularity over the years as they require no 
additional substrate or conenzymes to fluoresce, and rarely causes phototoxicity in living 
cells or whole organisms. Their applications as tools in biological researches are 
numerous, including as minimally invasive markers to track and quantify individual or 
multiple protein species, as probes to monitor protein-protein interactions, as photo-
modulatable proteins to highlight and follow the fate of specific protein populations 
within a cell, and as biosensors to describe biological events and signals [Lippincott-
Schwartz and Patterson, 2003; Zhang et al., 2002].  
Along with the continued advances in genetically fine-tuning the properties of fluorescent 
protein variants to increase brightness levels, improve photostability, larger Stokes shift, 
better expression and maturation in mammalian cells, it is important for the modern 
imaging technology to keep pace with these developments. More sensitive and quicker 
camera systems, filter systems for optimally detecting different fluorophores, superior 
software for quantifying and discriminating fluorescent signals, and hardware for 
photobleaching and photoactivating geometrically defined spatial patterns are desirable 
[Lippincott-Schwartz and Patterson, 2003].  
Greater understanding on how the fluorescent proteins work also led to their creative 
usage in labelling by researchers, and with combination of different microscopy 
techniques to reveal exciting new insights into the biology of living cells. Not only are 
fluorescent proteins used in elucidating the protein dynamics of cells, they are also very 
useful in visualizing pathogen-host interactions in cells. Van der Schaar et al interestingly 
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used a lipophilic dye, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-
chlorobenzenesulfonate salt (DiD), to fluorescently label DENV for tracking of the early 
cellular entry process [van der Schaar et al., 2008; van der Schaar et al., 2007]. Using this 
method, they were able to track single virus particles and characterize the dynamics of 
viral transport in the cell.  
1.6. Gaps in knowledge and Hypothesis/Objectives of this study 
As most endemic countries have 4 circulating serotypes of DENV, the burden of 
epidemic DF and DHF remains very high until a safe tetravalent dengue vaccine becomes 
available. In order to overcome the challenges in vaccine production, a reliable surrogate 
marker for immunity needs to be identified. Plaque reduction neutralization tests (PRNT) 
have been the gold standard for determining the serotype that an individual was exposed 
with previously in an uncomplicated scenario. However, distinguishing the actual 
serotypes a person was infected with previously may not be that straightforward in the 
event of secondary infection or immunization with Japanese encephalitis or yellow fever 
virus, due to presence of cross-reactive antibodies. Greater insights into how homotypic 
or cross-reacting antibody neutralizes the virus would provide the much needed correlates 
of immune-related protection to the vaccines and would expedite the development of new 
vaccines.  
Although the exact pathogenesis of DENV remains unclear to date, monocytes appear to 
have a central role in the clearance of antibody-virus immune complexes. It is thus to the 
interest of our laboratory to understand antibody-mediated neutralization or enhancement 
of DENV through the early interactions of antibody-DENV complexes with monocytes 
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and subsequently tease out the mechanisms that lead to the different outcomes of dengue 
infection. Equipped with that knowledge, we can then develop an assay that allows us to 
differentiate protective homotypic antibodies from the less protective cross-reacting 
antibodies. This would provide the much needed test to accelerate vaccine development. 
In the scope of this thesis, we will be focusing on antibody-mediated neutralization of 
DENV. Preliminary findings from our laboratory using DiD labelled DENV and  2 well-
characterized mabs, namely 3H5 and 4G2 [Henchal et al., 1982; Henchal et al., 1983] 
show that DENV complexes formed with minimally neutralizing amounts of homotypic 
3H5 antibody interact with THP-1 cells (monocytic cell line) differently compared to that 
of cross-reactive 4G2 antibody. As the minimally neutralizing concentrations of 3H5 
(3µg/ml) and 4G2 (100µg/ml) are very different, we hypothesized that at these 
concentrations of antibodies, the complexes formed interact differentially with the 
monocytes, possibly through the engagement of different Fc receptors, and hence 
different fates along the endocytic pathways. We also hypothesized the differential 
interaction with the Fc receptors could be due to different complex sizes formed at the 
different antibody concentrations.  
To test our hypotheses, we have four specific aims. 
Specific aims: 
1) Fluorescent label DENV 
In our previous study, a lipophilic fluorescent dye DiD labelled DENV was used to 
visualize its trafficking into endosomal pathway. However, as the DiD dye is largely 
quenched when in close-proximity to each other (e.g. on virus membrane), it is difficult 
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to look at early virus-cell interactions prior to fusion (where the lipids would then be 
diluted out and fluorescence increases dramatically). Freezing and thawing of DiD-
labelled virus might also cause the leaking of the dye from the virus membrane, hence the 
labelled virus can only be kept at 4°C for a short period of time. Freshly labelled virus 
needs to be prepared for each experiment. Thus it is necessary to explore fluorescence-
labelling of DENV with another dye that is unquenched extracellularly and with stable 
conjugation to the virus so that a large batch of labelled virus can be made and use in 
multiple experiments for consistency.  
Alexa Fluor dyes are a natural choice as they are more photostable and less sensitive to 
low pH, thus making them ideal to study endocytic trafficking. They also come 
conveniently in amine-reactive esters that conjugate permanently to the proteins. 
However, as they bind to the protein part of the virus, most likely to the abundant E 
proteins on the surface, careful optimization is necessary to ensure that labelled virions 
remain infective. Hence the first part of the MSc project was aimed at fluorescence 
labelling with Alexa Fluor dyes and characterizing the labelled virions. 
2) Visualizing the fate of antibody-DENV complexes in monocytes 
We next sought to visualize the early interactions of the complexes with monocytes and 
their subsequent sub-cellular localization through confocal microscopy, using the two 
mabs and the Alexa Fluor labelled DENV in THP-1 cell line. The fate of the antibody-
DENV complexes in THP-1 cells through the early endosomal and late endosomal 
network, using EEA-1 and LAMP1 as their respective markers, would be tracked and 
compared in a time course manner up to 2 hours. These experiments will be repeated on 
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primary monocytes to verify that the observations can also be reproduced in primary 
cultures. 
3) Fc receptor engagement 
Monocytes normally express more than one Fc receptor, mainly FcγRI and FcγRII, on 
their surfaces. Antibody-antigen complexes interaction with Fc receptor bearing cells is 
most likely through the Fc receptors. As such, one possible explanation for any 
differential interaction with the monocytes would be different Fc receptor engagement by 
the complexes. Hence, we would next elucidate the Fc recptor utilization by complexes 
formed with 3H5 or 4G2 mabs using confocal microscopy and this will shed light on any 
preferential Fc receptor employment in an environment where both FcγRs are 
simultaneously expressed. 
4) Concentration and complex sizes 
Being bivalent antibodies, IgGs are capable of binding to and cross-linking antigens into 
aggregates. Therefore, to test whether different antibody concentrations bring about 
DENV complexes of different sizes which could potentially influence the Fc receptor 
interactions on monocytes surface, we would determine and compare the sizes of DENV 


















2. Materials and methods 
2.1. Cell culture 
All cells and hybridomas were obtained from American Type Culture Collection (ATCC, 
Manassas, Va), and all cell culture media and supplements were purchased from Gibco 
(Invitrogen, Singapore). Baby hamster kidney BHK-21 cells were maintained in Roswell 
Park Memorial Institute 1640 medium (RPMI-1640), supplemented with 10% fetal 
bovine serum, penicillin (100U/ml) and streptomycin (100µg/ml) at 37°C with 5% CO2. 
African green monkey kidney Vero cells were maintained in Media-199 (M199) 
supplemented with 10% fetal bovine serum and 4mM L-glutamine at 37°C with 5% CO2. 
Raji B cells transfected with DC-SIGN was a kind gift from Timothy H. Burgess (Naval 
Medical Research Centre, US) and maintained in RPMI medium supplemented with 10% 
fetal bovine serum at 37°C with 5% CO2. THP-1 cells were maintained in RPMI-1640 
supplemented with 0.05mM 2-mercaptoethanol and 10% fetal bovine serum at 37°C with 
5% CO2. Mouse anti-dengue virus serotype 2 E protein monoclonal antibody hybridoma, 
3H5 (ATCC: HB46) and mouse anti-flavivirus E protein antibody hybridoma, 4G2 
(ATCC: HB112), were maintained in RPMI-1640 supplemented with 10% fetal bovine 
serum. 
2.2. Primary monocytes culture 
Venous blood from the principal investigator was collected in BD sodium heparin 
vacutainers (Biomed Diagnostics, Singapore). The blood was then diluted with 2 volumes 
of 0.5% bovine serum albumin (BSA, Sigma Aldrich, Singapore) in phosphate buffered 
solution (PBS, 1st Base, Singapore) (0.5% PBS/BSA), and carefully layered onto Ficoll-
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hypaque (GE healthcare, Singapore). The blood was then subjected to centrifugation at 
750 x g, without brakes. The interphase cells containing the peripheral blood 
mononuclear cells (PBMCs) were aspirated and transferred to a clean tube. The PBMCs 
were washed 3 times with 0.5% PBS/BSA and resuspended in growth medium (RPMI-
1640 supplemented with 10% fetal bovine serum, 100U/ml penicillin and 100µg/ml 
streptomycin). The cells were then counted and seeded into T25 tissue culture flasks 
(NUNC, Bio Laboratories, Singapore) at 1x107 per flask. The cells were incubated at 
37°C, 5% CO2 for 2.5hrs to allow the monocytes to adhere to the flask surface. The 
adhered cells were washed 5 times with PBS to remove the non-adherent lymphocytes, 
and replenished with fresh growth medium. These monocytes were allowed to recover 
overnight at 37°C, 5% CO2 before use in experiments. 
2.3. Antibodies 
Mouse anti-human EEA1 and LAMP1 antibodies (BD biosciences, Biomed Diagnostics, 
Singapore) were used at 1:100 and 1:500 dilutions, respectively. Mouse anti-human 
FcγRI (CD64, clone 10.1, eBioscience, Biomed Diagnostics, Singapore) and FcγRII 
(CD32, clone IV.3, StemCell Technologies) antibodies were used at 1:1000 dilution. 
Purified human IgG antibodies were purchased from Sigma Adrich, Singapore. Alexa 
Fluor 488 (AF488) anti-mouse IgG and Alexa Fluor 647 (AF647) anti-human IgG 
antibodies were purchased from Invitrogen and used at 1:100 dilution. Goat anti-human 
IgG HRP antibody was purchased from Sigma Aldrich and used at 1:1000 dilution. 
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2.4. Virus culture and purification 
Dengue 2 virus (ST) strain was first isolated from a clinical sample in Singapore General 
Hospital using an Aedes albopictus mosquito cell line C6/36 and subsequently 
propagated in Vero cells. The culture supernatant was harvested when 75% or more of 
the cells showed cytopathic effect and clarified by centrifugation at 1000g for 30min at 
4°C. Virus in the resulting supernatant was concentrated by centrifugation at 30,000g for 
2 hours at 4°C. The pellet was resuspended in 5mM Hepes, 150mM NaCl, 0.1mM EDTA 
(HNE buffer, pH7.4) and further purified over 30% sucrose cushion by 
ultracentrifugation in Beckman SW41Ti rotor at 80,000g for 15 hours at 4°C. Purified 
virus was resuspended in HNE buffer and stored in 100ul aliquots at -80°C. A limiting 
dilution plaque assay was performed on BHK cell line to determine the viral titre in 
plaque forming units per millilitre (pfu/ml). 
2.5. Plaque assay 
Ten-fold serial dilutions of virus were added to BHK-21 cells in 24 well plates and 
incubated for 1hr at 37oC, with gentle rocking every 15 minutes. Media was then 
aspirated and replaced with 0.8% methyl-cellulose in maintenance medium (RPMI-1640, 
2% fetal bovine serum, penicillin and streptomycin). After 4 days at 37˚C, cells were 
fixed with 25% formaldehyde and stained with 0.5% crystal violet. The plates were 
washed, dried and the plaque forming units per ml (pfu/ml) calculated. 
2.6. Virus labelling 
For the initial experiment aimed at determining the optimal concentration of dye needed 
to fluorescently label dengue virus, Alexa Fluor 594 succinimidyl ester (AF594SE, 
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Molecular Probes, Invitrogen) was reconstituted in dimethyl sulfoxide (DMSO) or 0.2M 
sodium bicarbonate buffer, pH 8.3 (SBB) immediately before labelling, and added to 
approximately 3x107 pfu dengue virus diluted in SBB at final concentrations of 10, 
50,100, 200, 500 and 1000µM of dye, while stirring gently. The dye-virus mixture was 
incubated at room temperature for 1 hour with gentle inversions every 15 minutes. The 
labelling reaction was stopped by adding freshly prepared 1.5M hydroxylamine, pH 8.5 
(Sigma-Aldrich, Singapore) and incubated at room temperature for 1 hour with gentle 
inversions every 15 minutes. Labelled dengue virus was re-titrated after fluorescence 
labelling and tested for fluorescence using immunofluorescence assay.  
For subsequent AF594SE or AF488SE labelling involving a larger batch of virus, the dye 
was dissolved directly in SBB and the same labelling approach was employed as above. 
The labelled dengue virus was purified using Sephadex G-25 columns (Amersham, GE 
Healthcare, Singapore) to remove the excess dye. The labelled virus was stored in 100ul 
aliquots at -80°C, re-titrated and tested for fluorescence before use. 
2.7. Immunofluorescence assay of viral infection 
Equal volume of AF594-labelled dengue virus was incubated with Vero cells plated on 
coverslips for 10 minutes at 37°C, washed, fixed with 3% paraformaldehyde (pFA, 
Sigma-Aldrich, Singapore) and permeabilized with 0.1% saponin (Sigma-Aldrich, 
Singapore). The cells were then incubated for 1 hr with centrifugation clarified 
supernatant of 3H5 monoclonal antibody hybridoma culture, at room temperature. The 
cells were washed three times in wash buffer (PBS containing 1mM calcium chloride, 
1mM magnesium chloride and 0.1% saponin), followed by incubation with AF488 anti-
mouse IgG antibody for 45min at room temperature. Cells were then washed three times 
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in wash buffer, rinsed once in deionised water and mounted on to glass slides with 
Mowiol 4-88 (Calbiochem, San Diego, CA) with 2.5% Dabco (Sigma-Aldrich, 
Singapore). Cells were visualized at magnification x63 on a Leica Microsystem TCS SP5 
confocal microscope and merged images exported for processing. Processing of the 
images involved adjustment of the contrast on the images on a whole for clarity and 
exported in individual colours for unmerged images using Adobe Photoshop CS3 version 
10.  
2.8. Flow cytometry determination of percentage of labelled dengue virus 
Raji B cells transfected with DC-SIGN were counted, aliquoted, centrifuged and 
resuspended in AF488-labelled dengue virus at multiplicity of infection (MOI) of 1 and 
incubated for 10 minutes at 37°C, then fixed with 3% paraformaldehyde. The cells were 
then washed 2 times with FACS buffer consisting of PBS with 0.1% fetal bovine serum 
and permeabilised with 0.1% saponin in PBS. Cells were subsequently stained for the 
presence of dengue virus using anti-E protein monoclonal antibody, 3H5, and PE anti-
mouse anti-IgG antibody before reading on BD FACS Calibur machine and analyzed 
with CellQuest software, version 3.3 (Becton Dickinson). 
2.9. Detection by SYBR green-based real-time PCR 
Real-time detection of viral RNA was done as previously described ([Lai et al., 2007]) 
using pan-dengue forward and reverse primers with some modifications. Briefly, RNA 
extraction was carried out using QIAamp viral RNA mini kit for purified non-labelled 
and AF594-labelled dengue virus (AF594-DENV), or RNeasy mini kit (both from 
QIAGEN, Hilden, Germany) for total RNA extraction from cells according to 
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manufacturer’s instructions. Complementary DNA was synthesized using SuperScript III 
First Strand Synthesis System (Invitrogen, Singapore) following manufacturer’s 
instructions for random hexamers. RNA copy number was then determined by SYBR 
green-based real-time PCR on LightCycler 480 Real-Time PCR System (Roche 
Diagnostics, Penzberg, Germany). 
2.10. Growth kinetics  
Vero cells are seeded at 2 x 105 per well in 24 well plates and allowed to adhere at 37°C 
for 4 hours before infecting with MOI 0.1 of either purified dengue virus or AF594-
DENV for 1 hour at 37°C, with gentle rocking every 15 minutes. The cells were then 
washed 2 times with 1ml per well PBS and replaced with maintenance medium (MM, 
M199 with 2% FBS). Supernatant was harvested from wells and stored at -80°C for 
plaque assay, and cells were washed 2 times in PBS and lysed with RLT buffer provided 
in RNeasy mini kit at 0, 6, 8, 12, 24, 48 and 72 hours post adsorption. The cell lysates 
were stored frozen until all samples were collected and subsequently extracted according 
to kit’s protocol. Viral RNA was detected using real-time PCR. 
2.11. Humanization of 3H5 and 4G2 mouse monoclonal antibodies 
Chimeric forms of the mAb 3H5 (h3H5) and 4G2 (h4G2) containing mouse VH and VL 
sequences and human γ1 and κ constant sequences were constructed as previously 
described in Hanson et al [Hanson et al., 2006] by Angeline Lim.  
2.12. Binding affinity ELISA 
Nunc Maxisorp 96-well plate was coated with 100µl of 2x105 pfu/ml purified DENV 
(labelled or non-labelled) overnight at 4°C. The plate was washed 5 times with PBS 
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containing 0.05% Tween-20 (PBST), with 1 min intervals, blotted dry and blocked for 
1hr with 100ul of 1% skim milk in PBS at room temperature. The plate was washed 5 
times with PBST, with 1 min intervals, before the addition of 50µl/well two-fold serial 
dilutions of mouse 3H5/4G2 monoclonal antibodies or humanized 3H5/4G2 in 0.5% skim 
milk in PBS (quadruplicates). The primary antibodies were incubated for 1hr at 37°C, 
washed 5 times in PBST with 1 min intervals , before adding 25µl/well goat anti-human 
IgG HRP for 1hr at 37°C. The plate was then washed 5 times in PBST and blotted dry. 
100µl/well Tetramethylbenzidine (TMB) substrate was added and allowed colour to 
develop in the dark before stopping with 50µl of 2M H2SO4. The OD was then read at 
450nm. 
2.13. Titration of h3H5/h4G2 to determine neutralizing concentrations on 
monocytes 
 
Two-fold serial diluted h3H5 or h4G2 antibodies were allowed to complex with 2 x105 
pfu of DENV 2 ST strain at 37°C before adding to 2 x 104 THP-1 cells or primary 
monocytes (MOI 10). The culture supernatant was then harvested 72hrs post-infection for 
plaque assay. The neutralizing concentrations of h3H5 or h4G2 on THP-1 cells or 
primary monocytes were determined to be the highest dilution of antibodies that 
produced no plaques. 
2.14. DENV immune complex co-localization studies in monocytes 
 
Neutralizing concentrations of h3H5 or h4G2, or neutralizing concentration of h3H5 with 
the addition of purified human isotype control IgG to top up total antibody concentration 
to 100 or 400µg/ml, were incubated with 10 MOI of AF594-DENV for 1hr at 37°C and 
cooled on ice before adding to pre-cooled THP-1 cells or primary monocytes. The 
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mixture was further incubated for 15mins on ice to synchronize entry. The time course of 
5, 10, 30, 60 and 120mins was started by transferring the mixture to 37°C, and ended by 
transferring back to ice. The cells were then fixed in 3% pFA for 30mins on ice and 
centrifuged on to positively-charged glass slides (Menzel-Gläser, Germany) at 800rpm 
for 3min using a cytospin machine. The cells were then permeabilized with 0.1% saponin 
and stained for early endosome marker (EEA1), late endosome/lysosome marker 
(LAMP1), FcγRI or FcγRII at room temperature for 1hr. The slides were then washed 3 
times with PBS containing 0.1% saponin and incubated with AF488 anti-mouse IgG and 
AF647 anti-human IgG secondary antibodies for 45mins at room temperature in the dark. 
The slides were washed 3 times and rinsed once in distilled water before mounting in 
Mowiol 4-88 containing 2.5% Dabco. The cells were visualized at magnification x63 on 
a Leica Microsystem TCS SP5 or Carl Zeiss LSM 710 confocal microscopes and merged 
images exported for processing. Processing of the images involved adjustment of the 
contrast on the images on a whole for clarity and exported in individual colours for 
unmerged images using Adobe Photoshop CS3 version 10.  
2.15. Sucrose gradient analysis of DENV immune complex sizes 
 
Sucrose gradient was formed by careful layering of 10-60 sucrose solutions (in HNE 
buffer) in 10% increments, starting with the densest at the bottom, in 13.5ml Ultra-Clear 
tubes (Beckman Coulter, Singapore). The gradient was allowed to linearize overnight at 
4°C.  
Equal amounts of purified DENV were incubated with humanized antibodies at 3 or 
100µg/ml h3H5 IgG or h3H5 Fab (h3H5 IgG that was enzymatically digested to give 
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only 1 arm of the Fab fragment) at 33.3µg/ml (mole equivalent amount of 100µg/ml 
h3H5) or without antibodies (virus control) for 1hr at 37°C. The samples were then 
carefully layered on top of the linearized 10-60% sucrose gradient, and centrifuged 
overnight at 25,000rpm at 4°C, in SW41Ti rotor for 17hrs. Each gradient was then 
harvested in 0.25ml fractions in a drop wise manner from the bottom of the tube. 
Subsequently, the viral RNA was extracted from each fraction and quantified by real-
time PCR.  
2.16. Dynamic light scattering (DLS) analysis of DENV immune complex sizes 
 
Individual fractions from section 2.16 were also subjected to dynamic light scattering to 
determine the diameter of the complexes formed by different concentrations of the 
antibodies. 20µl of each fraction was loaded into Quartz cuvette for analysis by Zetasizer 
Nano S machine (Malvern Instruments, UK) at 37°C using 50% sucrose in HNE buffer as 
the dispersant. Data was then analysed using Zetasizer Nano software version 6.01. The 
diameter reports generated were average of more than 10 readings. 
2.17. Statistical analysis 
Statistical analyses were performed using unpaired Student’s t test on Graphpad Prism 5 

















3.1. Producing fluorescent DENV 
Results reported in this section has been published in Zhang et al, J Virol Methods 
2010;167:172-7. 
 
3.1.1. Alexa Fluor labelling of DENV 
To visualize the early interactions of DENV-antibody complexes with cells, we sought to 
label DENV with a suitable fluorophore. DENV surface has several identical protein 
subunits and can therefore be labelled at multiple sites using an amine reactive dye; the 
resulting fluorescence intensity may be sufficient to track the virus under a fluorescence 
microscope. Hence the goal here was to develop a simple procedure of labelling DENV 
with a fluorescent Alexa Fluor succinimidyl ester that results in minimal loss of 
infectivity post-labelling. Alexa Fluor dye was chosen as it has better photostability and 
signal intensity compared to other common fluorophores such as fluorescein 
isothiocyanate (FITC) or cyanine 3-bihexanoic acid (Cy3). In addition, Alexa Fluor dyes 
are stable at a lower pH compared to the common fluorophores, which could be useful for 
visualizing labelled viral particles as they move through the acidic compartments of 
endosomes post-infection. Furthermore, the permanence of covalent conjugation of the 
fluorophores to the surface proteins allows for storage of batch-labelled virus at -80°C, 
providing uniformity across multiple experiments.  
Labelling was initially carried out according to the protein labelling protocol supplied by 
the manufacturer that requires the reconstitution of Alexa Fluor 594 succinimidyl ester 
(AF594SE) in DMSO. To determine the optimum concentration of AF594SE to use for 
labelling of DENV to obtain maximum fluorescence and minimum loss in viable virus 
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titre, a range of concentrations (10, 50, 100, 200, 500 and 1000μM) were tested. The 
AF594 labelled-DENV (AF594-DENV) was then re-titrated by plaque assay (Fig. 3-1a).  
Approximately 31- to 58-fold reductions in titre were obtained when DENV was labelled 
with 10μM to 500μM of AF594SE, while DENV labelled with 1mM dye was reduced 
approximately 796-fold compared to the virus control.  
The infectivity of the labelled DENV was determined by immunofluorescence staining. 
Vero cells seeded on coverslips were incubated with equal amounts of DENV labelled 
with different concentrations of dye. The cells were then fixed, stained for E protein and 
visualized using laser-scanning confocal microscope. The cells showed little to no 
staining of E protein across the concentrations of AF594SE used (Fig. 3-1b). Taken 
collectively, these data indicate that there was a significant drop in virus titre post 
labelling.  A plausible explanation is that DMSO has adverse effects on virus viability.  
Hence, an alternative method to label DENV without the use of DMSO was sought.  
Since the AF594SE dye is highly soluble in aqueous solution, we dissolved the dye 
directly in the sodium bicarbonate labelling buffer (SBB), without DMSO. The 
fluorescence labelling experiment was repeated with the same range of dye 
concentrations, but this time with the AF594SE reconstituted in SBB. The titre of DENV 
labelled with 10μM to 100μM of AF594SE dye showed approximately 15-fold reduction, 
and DENV labelled with 500μM and 200μM AF594SE dye showed approximately 26 to 
29-fold reductions, respectively, compared to equivalent number of non-labelled virus. 
DENV labelled with 1mM of AF594SE dye showed 82-fold reduction in titre. 
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Using the modified labelling protocol, E protein can clearly be detected by 
immunofluorescence staining in the cells inoculated with the AF594-DENV across the 
range of dye concentrations used. However, its intensity diminished substantially for 
DENV labelled with 500μM and 1mM of the dye, indicating a reduction in virus 
infectivity post-labelling with higher concentrations of dye (Fig. 3-1c). This was 
consistent with the plaque assay results. DENV labelled with 10μM and 50μM of dye 
showed no discernable AF594 fluorescence, while DENV labelled with 100μM and 
200μM of AF594SE dye displayed high AF594 fluorescence which co-localized well 
with the E protein staining. Only weak AF594 fluorescence could be detected in cells 
inoculated with DENV labelled with 500μM and 1mM of AF594SE dye. 
The above results indicate that the modified protocol is able to produce labelled DENV 
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Figure 3-1 Dengue virus viability post AF594 labelling 
Purified dengue virus was labelled with various concentrations of AF594SE dye 
dissolved in DMSO or SBB for 1 hour at room temperature. (a) The labelled virus was 
then re-titrated post-labelling by plaque assay. Bar diagram shows average virus titre of 
four determinations, pre- and post-labelling. Error bars indicate standard deviation. The 
labelled virus with dye dissolved in DMSO (b) or SBB (c) was also tested for 
fluorescence intensity by immunofluorescence assay. Vero cells seeded on coverslips the 
day prior are infected with labelled DENV for 10 minutes at 37°C. The cells were 
subsequently fixed and labelled with anti-E antibody, and examined for co-localization of 
E protein (green) and AF594 labelling (red). Fluorescent signals are visualized under 63X 
magnification using Leica Microsystem TCS SP5 confocal microscope. Scale bar is 




3.1.2. Efficiency of Alexa Fluor dye labelling 
To estimate the percentage of virus labelled with the fluorescence dye using this modified 
method, flow cytometric studies were carried out using DENV labelled with AF488SE 
dye (AF488-DENV). DC-SIGN transfected Raji B cells were infected with AF488-
DENV at a MOI of 1, stained for presence of E protein using 3H5 monoclonal antibody 
and analysed by flow cytometry. Compared to the uninfected Raji B cells with DC-SIGN, 
approximately 81.4% of the cells following infection were positive for the E protein. Of 
these cells, 58.4% were positive for both E protein and AF488 (Fig. 3-3a), suggesting that 
approximately 71% of the virions were labelled with the Alexa Fluor dye.  
Although AF594-DENV could not be assessed for efficiency of labelling on the flow 
cytometer used, due to the lack of appropriate excitation laser, Pearson’s correlation 
values obtained from co-localization studies using confocal microscopy revealed that 
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Figure 3-2 Efficiency of Alexa Fluor dye labelling as a function of percentage 
infected 
 
Raji B cells transfected with DC-SIGN were infected at a MOI of 1 with AF488-DENV 
for 10 minutes at 37°C, fixed and stained for presence of E protein. Fluorescence was 
then measured using BD FACS Calibur (a).  Close to 100% of uninfected Raji B cells 
with DC-SIGN were double negative for both Alexa Fluor and anti-E antibody signals, 
whereas approximately 81% of the infected cells stained positive for E protein, and 
approximately 71% of which were also positive for Alexa Fluor 488 fluorescence, 
suggesting that approximately 71% of the virions were labelled with the dye.  Confocal 
microscope analysis of Vero cells infected with AF594-DENV (red) and stained for E 
protein (green) showed a mean Pearson’s correlation of 0.677 ± 0.053 (Mean ± SD) (b), 




3.1.3. Reproducibility of labelling 
Three independent AF594SE labelling experiments were performed with similar starting 
titre of 2x108 pfu of purified DENV using the modified protocol. The titre post-labelling 
was then determined by plaque assay. All three experiments showed 3- to 8-fold 
reduction in titre post-labelling and column purification, from a mean titre of 2.21x108 
(SD = 3.68x107) to 3.78x107 (SD = 1.5x107). To exclude the possibility that the reduction 
in titre post-labelling was due to a loss in infectivity of the virus, the ratio of RNA copy 
number to plaque forming unit of DENV pre- and post-labelling was analysed from one 
of these batches of labelled virus. No significant difference in the viral RNA copy 
number to plaque forming unit ratio was observed between pre- and post-labelled virus 
(Table 3-1, p > 0.5), indicating that the fall in titre was not due to inactivation of the 




Table 3-1  
Viral RNA copy number to infectious particle ratio 
 Titre (pfu/ml) RNA copy number (/ml) RNA copy 
number/pfu 
AF594-DENV 3.5 x 107  6.27 x 108 ± 2.61 x 108 17.9 ± 7.45 
Purified DENV 1.0 x 109  1.67 x 1010 ± 1.30 x 1010 16.7 ± 12.96 
 
Viral RNA was extracted from purified non-labelled DENV or AF594-DENV and RNA 
copy number quantitated by real-time PCR.  The RNA copy number was then divided by 
the titre to obtain a ratio for both non-labelled DENV (16.7) and AF594-DENV (17.9). 
The similar ratios indicated that both labelled and non-labelled DENV have comparable 
infectious/non-infectious proportions, suggesting that the labelling process did not 




3.1.4. Growth kinetics of labelled DENV 
As the labelled virus would be used to track the progression of virus through cellular 
compartments, we tested if labelling altered the efficiency of virus replication. Vero cells 
were infected with either purified non-labelled or AF594-DENV at a MOI of 0.1. Culture 
supernatant and cell lysates were collected up to 72 hours and assayed for virus titre in 
supernatant as well as viral RNA in the cell lysates. No significant difference was 
observed between labelled and unlabelled virus for both viral RNA copy number and the 
number of infectious particles in the supernatant of the culture (Fig. 3-3) (P > 0.5). The 
data indicates that the attachment of the fluorophores at the concentration used did not 
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Figure 3-3 Comparing the growth kinetics of purified non-labelled and labelled 
DENV 
Vero cells were plated and allowed to adhere before infecting at a MOI of 0.1 with either 
AF594-DENV or non-labelled DENV. Viral RNA copy number in cell lysates was 
determined to assess viral replication (a) and supernatant was assayed for infectious 
particles by plaque assay (b). No significant difference was observed between the growth 
curves of labelled and non-labelled dengue virus in RNA copy number (P = 0.8630) and 
total pfu (P = 0.8191). Each point is an average of four determinations. 
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3.2. Visualizing the fate of antibody-DENV complexes in monocytes 
3.2.1. Humanized 3H5 and 4G2 
To describe the early interactions of DENV-antibody complexes with human monocytes, 
two mouse mabs, namely 3H5 and 4G2 [Henchal et al., 1982; Henchal et al., 1983] were 
used. 3H5 mab is a DENV-2 type-specific and potently neutralizing antibody that binds 
to an epitope in N-terminal region and FG loops of the lateral ridge of domain III on the 
E protein [Trirawatanapong et al., 1992], while 4G2 mab is a flavivirus cross-reactive 
antibody that recognises an epitope in the fusion peptide of domain II of E protein [Crill 
and Chang, 2004]. However, the use of these mabs with human monocytes requires the 
switch of the mouse Fc portion of the antibodies to that of human Fc region to ensure the 
correct engagement of the Fc receptors on the human cells. Chimeric forms of the mAb 
3H5 (h3H5) and 4G2 (h4G2) containing mouse VH and VL sequences and human γ1 and 
κ constant sequences were constructed as previously described in Hanson et al [Hanson et 
al., 2006]. These chimeric IgG1 antibodies retained similar binding characteristics to 
DENV-2 as their parent mabs, indicated by the similarity of their respective Kd values 
(p>0.05) (Table 3-2). The humanized antibodies were also tested for their binding 
affinities to the AF594-DENV. There was no significant difference in binding of h3H5 
between labelled and non-labelled virus (p>0.05); however, h4G2 has an increased 





Table 3-2  




Before humanization After humanization 
3H5 0.5189 ± 0.0935 0.3881 ± 0.0499  0.233 
4G2 1.3560 ± 0.4630 1.5550 ± 0.2962 0.721 
 
Kd values were determined by non-linear regression analysis. There were no differences 
in binding affinity to DENV-2 before and after humanization (P-value>0.05, not 





Table 3-3  




AF594-DENV Non-labelled DENV 
h3H5 0.1124 ± 0.0111 0.0913 ± 0.0167 0.289 
h4G2 0.2612 ± 0.0301 0.5434 ± 0.1052 0.013 
 
Kd values were determined by non-linear regression analysis. There was no significant 
difference in binding of h3H5 to labelled and non-labelled DENV (P-value>0.05, not 





3.2.2. Determining the neutralizing concentrations of h3H5 and h4G2 on monocytes 
Two-fold serial dilutions of h3H5 or h4G2 were allowed to complex with 10 MOI of 
DENV before the mixture was added to the THP-1 cells or primary monocytes. The 
supernatant was then harvested 72 hours later for plaque assay. The minimum 
neutralizing concentrations of antibodies on THP-1 (Fig. 3-4a) or primary monocytes 
(Fig. 3-4b) were determined to be the highest dilution that produced no plaques. 
Humanized 3H5 fully neutralized DENV between the range of 3 to 400µg/ml antibodies, 
with the minimum neutralizing concentration being 3µg/ml on THP-1 cells and 6µg/ml 
on primary monocytes. Humanized 4G2 neutralized DENV at a concentration of 
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Figure 3-4 Neutralizing concentrations of h3H5 and h4G2 on monocytes 
Two-fold serial dilutions of h3H5 or h4G2 were incubated with DENV for 1hr before 
adding to (a) THP-1 cells, or (b) primary monocytes, and cultured for 72 hours. The 
supernatant was then harvested and plaque assay done to determine the titre. The graphs 
above show the percentage neutralization of DENV at various antibody concentrations 
compared to virus control. The highest dilution that resulted in no plaques was taken to 
be the minimum neutralizing concentration for each antibody. Each point is an average of 
at least 3 determinations. (Graph (a) from Tan Hwee Cheng)  
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3.2.3. Visualizing the entry and endosomal trafficking of antibody-virus complexes 
in THP-1 monocytic cell line 
To understand the early events of antibody-DENV complexes (formed with h3H5 or 
h4G2) interaction with monocytes that leads to subsequent neutralization of the virus, a 
time course experiment was performed and the events visualized by confocal microscopy. 
Neutralizing concentrations of h3H5 (3µg/ml) or h4G2 (100µg/ml) were complexed with 
10 MOI of AF594-DENV for 1hr at 37°C. The immune complexes were incubated with 
THP-1 cells on ice to allow synchronization of entry and time course started when 
temperature was raised to 37°C. The cells were subsequently fixed and stained for early 
endosome marker (EEA1) or late endosome/lysosome marker (LAMP-1) after 5, 10, 30, 
60 or 120min incubation at 37°C, before viewing under 63x magnification on a confocal 
microscope. The samples were also stained with anti-human IgG secondary antibodies to 
confirm that the humanized antibodies co-localized with DENV.  
With h3H5, the labelled virus and human antibody signals could be seen co-localizing 
with LAMP-1 in approximately 2-3% of the cells after 5 and 10min incubation at 37oC 
(Fig. 3-5). After 30min, the percentage of cells showing antibody-DENV complexes in 
LAMP-1 positive compartments increased to 4-5%. The viral proteins and h3H5 could 
still be observed in the LAMP-1 positive compartments at the 1 and 2hr time points.  
With h4G2, however, significantly less immune complexes were attached to the cells and 
they appeared to be trapped on the cell surface, indicated by the reduced number of 
AF594-DENV spots and dimmer fluorescence, for all time points taken in the first hour 





with LAMP-1 positive compartments were observed at the 2hr time point in 1-2% of the 
cells.  
As no productive replication of the virus occurred in THP-1 with these concentrations of 
mabs, the observations suggest that the 2 mabs resulted in the formation of immune 
complexes that interacted differently with THP-1. At the minimum concentration for 
h3H5 to neutralize 10 MOI of DENV (3µg/ml), antibody-DENV complexes were 
internalized early and extensive co-localization of the complexes in the LAMP-1 positive 
compartments was observed. In contrast, no sub-cellular trafficking of the antibody-virus 
complexes was observed with h4G2 at its minimum neutralizing concentration 





Figure 3-5 Neutralizing h3H5-DENV complexes entry and transport in THP-1 
Fluorescence images show the tracking of AF594-DENV bound complexed with neutralizing amounts of h3H5 (3µg/ml) in THP-1 cells over time. 
The left panel shows cells stained for the early endosomal marker, EEA1, and the right panel shows staining for late endosomal marker, LAMP-1. 
3H5 antibody-DENV complexes were rapid internalized and trafficked to LAMP-1 positive compartments. Endosomal markers are in green, 








Figure 3-6 Neutralizing h4G2-DENV complexes entry and transport in THP-1 
Fluorescence images show the tracking of AF594-DENV bound complexed with neutralizing amounts of h4G2 (100µg/ml) in THP-1 cells over 
time. The left panel shows cells stained for EEA1 and the right panel shows staining for LAMP-1. Significantly less h4G2-DENV complexes were 
attached to cells and internalization was inhibited till 2 hr time point. Endosomal markers are in green, DENV in red, h4G2 in blue and white 




3.2.4. Primary monocytes 
The above observations were made using THP-1 cell line. To rule out any artefacts 
due to the choice of cell line used, we repeated the experiments using primary 
monocyte cultures. 
Primary monocytes were isolated from peripheral blood using Ficoll density gradient 
centrifugation and plastic adherence as described in the materials and methods. The 
monocytes were then cultured overnight at 37°C, without any cytokine stimulation for 
maturation, before use. This method of isolation yielded at least 80% monocytes (gate 
R1), with a low percentage of lymphocytes contamination (gate R2), as confirmed by 




 Figure 3-7 Primary monocytes yield  
Primary monocytes were isolated from peripheral blood using Ficoll density 
centrifugation and plastic adherence. Each isolation yielded at least 80% purity by 






3.2.5. Antibody-DENV immune complex interactions with primary monocytes 
 
The AF594-DENV was complexed with minimally neutralizing concentrations of 
h3H5 (6µg/ml) or h4G2 (100µg/ml) and added to the primary monocytes. The fate of 
the complexes was then followed at different time points using confocal microscopy. 
Similar to what was observed with THP-1 cell line, DENV complexed with 6µg/ml of 
h3H5 were internalized by the primary monocytes after incubation at 37°C. At the 
5min time point, antibody-DENV complexes could be seen near the surface of the 
cells, with an occasional co-localization of a DENV spot with EEA1 but no co-
localization with LAMP-1 (Fig. 3-8). However, at 10min time point, majority of the 
complexes was already within LAMP-1 positive compartments. By 30, 60 and 
120min time points, approximately 10% of the cells observed had the complexes co-
localizing strongly with LAMP-1 positive compartments.   
Humanized 4G2 bound DENV, however, was able to attach to the primary monocytes 
but entry into the cells was inhibited at the early time points. In approximately 5-10% 
of the cells, the complexes were seen to line the surface at all time points observed up 
to 60min. At the 2hr time point, h4G2 bound DENV can be detected in the LAMP-1 








Figure 3-8 Entry and endocytic trafficking of h3H5-opsonized DENV in primary monocytes 
Fluorescence images show the tracking of AF594-DENV bound complexed with neutralizing amounts of h3H5 in primary monocytes over time. 
The left panel shows cells stained for the early endosomal marker, EEA1, and the right panel shows staining for late endosomal/lysosome marker, 








Figure 3-9 Entry and endocytic trafficking of h4G2-opsonized DENV in primary monocytes 
Fluorescence images show the tracking of AF594-DENV bound complexed with neutralizing amounts of h4G2 in primary monocytes over time. 
The left panel shows cells stained for the early endosomal marker, EEA1, and the right panel shows staining for late endosomal marker, LAMP-1. 





3.3. Fc receptor requirement for internalization  
 
Fc receptors (FcR) are important in mediating immune complex attachment and 
internalization into monocytes. Two types of FcγRs, FcγRI and FcγRII, are present on 
both THP-1 cells and primary monocytes (Fig. 3-10). Although both FcγRs have been 
shown to mediate enhancement of DENV infection in monocytes [Kou et al., 2008; 
Littaua et al., 1990], much less is known about their role in mediating viral clearance 
in the presence of neutralizing antibodies in this cells. FcγRI has been shown to be 
important in mediating clearance of neutralizing antibody-DENV complex in a recent 
study using CV-1 cells transfected with FcγRI/γ [Rodrigo et al., 2009]. However, this 
study cannot explain how antibody-DENV complexes interact with monocytes where 
both FcγRs are naturally expressed simultaneously. Since FcγRI and FcγRIIa have 
fundamental differences in their intracellular signaling pathways and antigen 
processing/presentation when activated [Dai et al., 2009], differential receptor 
engagement could explain the distinct fates of the DENV immune complexes in 
monocytes. Hence, having a tool available to visualize this interaction, AF594-DENV 
was used to shed some light on the FcγR engagement by the different complexes.  
THP-1 cells were incubated with AF594-DENV complexed with either h3H5 at 
3µg/ml or h4G2 at100µg/ml for 30 and/or 120min at 37°C, fixed and stained for 
FcγRI or FcRγII before viewing with a confocal microscope. At 30min, DENV 
opsonised by h3H5 interacts with both FcγRI and FcRγII on the surface of the cells, 
but those complexes that were internalized, co-localized mainly with FcγRI (Fig. 3-
11). Although a few DENV spots can be seen to co-localize with FcRγII, they 
constitute only a minority of the observation. This effect is much more pronounced on 
primary monocytes (Fig. 3-12). 
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Humanized 4G2 bound DENV attached to THP-1 cell surface by both FcγRI and 
FcRγII at 30min and remained on the outside of the cells (Fig. 3-11). The complexes 
also appeared to cluster the Fc receptors as shown by the increased intensity of FcγRI 
or FcRγII staining around the complexes. This was not observed with the h3H5-bound 
DENV. The complexes that had entered the cells by 2hr after temperature shift to 
37°C, appeared to co-localize to the same extent with both FcγRI and FcRγII. Again, 
this effect is more evident with primary monocytes (Fig. 3-12). 
These results indicated that DENV-h3H5 complexes can attach to either FcγRI or 
FcRγII on the surface of the cells but internalization occurred primarily through 
FcγRI; whereas for h4G2-bound virus, the immune complexes are able to bind to both 
FcγRI and FcRγII on the cell surface but opsonization is inhibited until after 2 hours 
of incubation.  The subsequent uptake of the immune complex appeared to be 
mediated by both FcγRI and FcRγII.  
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 Figure 3-10 Fc gamma receptors expression on monocytes 
Both FcγRI and FcRγII are expressed on THP-1 cell line and primary monocytes 










Figure 3-11 Fc receptor requirements by h3H5 or h4G2-opsonized DENV in THP-1 cells 
Fluorescence images show the tracking of AF594-DENV bound complexed with neutralizing amounts of h3H5 (h3H5N) or h4G2 
(h4G2N) in THP-1 cells after 30min and/or 120min incubation at 37°C. The left panel shows cells stained for FcγRI, and the right 







Figure 3-12 Fc receptor requirements by h3H5 or h4G2-opsonized DENV in primary monocytes 
Fluorescence images show the tracking of AF594-DENV bound complexed with neutralizing amounts of h3H5 (h3H5N) or h4G2 
(h4G2N) in primary monocytes after 30min and/or 120min incubation at 37°C. The left panel shows cells stained for FcγRI, and the 




3.4. Inhibition of immune complex uptake 
3.4.1. Concentration dependence 
We next evaluated if the concentration of antibodies influences how the complexes 
interact with monocytes. Humanized 3H5 has a broad range of neutralizing activity on 
DENV-2 (3 to 400µg/ml) (Figure 3-4a). To test the effect of high antibody 
concentrations on the complexes interaction with monocytes, h3H5 concentration was 
increased to 100 and 400µg/ml, similar to the neutralizing concentration of h4G2. At 
these concentrations of h3H5, the proportion of cells positive for AF594-DENV 
fluorescence reduced markedly from 4-5% to approximately 1-2% at 30min time 
point, compared to h3H5 at 3µg/ml. Of these, majority of the antibody-DENV 
complexes lined the surface of the cells with occasional entry of 1 or 2 complexes into 
LAMP-1 positive compartments just below cell surface (Fig. 3-13a, c). Similarly, 
complete inhibition of opsonisation can be observed in primary monocytes at 
400µg/ml of 3H5 (Fig. 3-13d), although 100g/ml of the antibody did not stop uptake 
of the complexes (Fig. 3-13b).  Taken collectively, these results indicate that the 
concentration of DENV antibody affects the efficiency of opsonization in monocytes. 
3.4.2. Competition for Fc receptors 
An obvious explanation for the above observation is that excess antibodies competed 
with the immune complexes for the same Fc receptors. To test this possibility, we 
compared the sub-cellular localization of antibody-DENV complexes neutralized with 
100 or 400µg/ml of h3H5 to that of 3µg/ml but with an addition of isotype control 
antibodies to give a total antibody concentration of 100 or 400µg/ml. The addition of 
isotype control antibodies did not inhibit internalization of the virus in both THP-1 





14). These observations indicate that inhibition of FcγR-mediated internalization by 
high concentration of h3H5 is likely to be a function of specific antibody-antigen 






Figure 3-13 Effect of increased antibody concentrations on endocytic trafficking of DENV 
Fluorescence images show the tracking of AF594-DENV bound complexed with 100 or 400µg/ml of h3H5 in THP-1 cells (left panel, 
a, c) or primary monocytes (right panel, b, d) at 30min. The cells were stained for LAMP-1 and viewed with confocal microscope. 









Figure 3-14 Competition for Fc receptors 
Fluorescence images show the tracking of AF594-DENV bound complexed with neutralizing amounts of h3H5 with the addition of 
isotype control antibodies to a total concentration of 100 or 400µg/ml in THP-1 cells (left panel, a, c) or primary monocytes (right 
panel, b, d) at 30min time point. The cells were stained for LAMP-1 and viewed with confocal microscope. White arrows indicate 







3.4.3. Immune complex size and internalization 
As competition for FcγR by free antibodies has been excluded as a possible 
explanation (see section 3.4.2), we hypothesized that the inhibition of uptake of 
DENV complexes formed at high concentrations of antibodies into monocytes might 
be dependent on their size.  Besides binding to epitopes on the DENV E protein and 
thus inhibiting their ability to interact with the relevant cellular receptors or uncoating 
of the virus post-uptake, antibodies can also aggregate viruses and how different 
antibody concentrations affect the size of these viral aggregates as well as its 
subsequent interaction with monocytes, is unknown. To test this hypothesis, the 
immune complexes formed at 3 or 100µg/ml of h3H5 IgG or single Fab arm of h3H5 
antibodies or virus only control were subjected to sucrose gradient and dynamic light 
scattering (DLS) analyses. 
3.4.3.1. Sucrose gradient separation of immune complex sizes 
 
Being bivalent antibodies, h3H5 may form a wide variety of complexes with different 
compositions of sizes and consequently, different sedimentation coefficients. Hence, a 
sucrose gradient would be useful in separating such a heterogeneous mixture and 
determining the most abundant complex size(s). Viral RNA were quantified from 
each fraction and plotted against its fraction number to give a distribution curve (Fig. 
3-15a). The distribution curves for the different conditions were then compared 
against that of the virus control for any change brought about by the addition of 
antibodies.  A lower fraction number of the gradient would thus indicate higher 
particle density. 
Viral RNA distribution curve of the virus only control tube showed a peak at fraction 
15, indicating the position where majority of the free virions would reside in the 10-
115 
 
60% sucrose gradient. With the addition of h3H5 IgG, there was an obvious shift of 
the curves to the left of that of the virus control, indicating that the antibodies 
increased the sedimentation of the virus, suggesting the formation of aggregates. At 
3µg/ml of h3H5 IgG, the peak shifted to fraction 12 and at 100µg/ml of h3H5 IgG, 
there was a further shift of the peak to fraction 9. Unlike the virus control where the 
spread of the curve is small with a sharp peak around fraction 15 (suggesting that the 
virions were mostly uniformly sized), the spread of the distribution curves for DENV 
with h3H5 IgG became wider (suggesting that the immune complexes formed were 
heterogeneous in size). This shift in curves cannot be explained solely by the 
attachment of antibodies to the surface of DENV as the addition of h3H5 Fab brought 
about only a slight shift of 1 fraction to the left of virus control with little change to 
the shape of the curve. Since the h3H5 Fab has the same binding affinity as the 
parental h3H5 IgG but lacks both arms of the antigen-binding region, it is able to bind 
to DENV but not cross-link them. Hence, it was expected that the shift due to the 
attached h3H5 Fab on the surface of the virions should be minimal. This trend is 
reproducible over three independent experiments. 
3.4.3.2. Immune complex size by Dynamic Light Scattering (DLS) 
 
To confirm that the shift in fraction numbers were indeed due to the increase in 
complex sizes, individual fractions were analyzed using DLS. The DLS machine 
works by shining a monochromatic light beam, such as a laser, onto a solution where 
particles in Brownian motion causes a Doppler Shift when the light hits the moving 
particle, thus changing the wavelength of the incoming light falling on the detector. 
This change was then related to the size of the particle using Stokes-Einstein equation 
to give a size distribution of the particles in suspension.  
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DLS analysis of virus only control showed that majority of the particles have an 
average size of 49.1nm in diameter (fraction 15), corresponding to the size of a single 
dengue virion (Fig. 3-15b). Addition of 3µg/ml of h3H5 increased the average 
diameter of the DENV complex to 64.5nm (fraction 12). An IgG molecule is 
approximately 15nm in length. Hence, it is likely that at this concentration of h3H5, 
majority of the particles had antibody bound to them, but did not cross-link adjacent 
virions to form aggregates. However, at 100µg/ml of h3H5, the average diameter of 
the complexes increased to 192.0nm (fraction 9), indicating an aggregate of at least 3 
virions in a row (Fig. 3-15c). With h3H5 Fab (approximately 7.5nm in length), the 
majority of the complexes were 57.7nm in diameter (fraction 14), signifying that the 
larger complex size formed with 100µg/ml of h3H5 IgG is specific action of antibody 
cross-linking and not due to addition of exogenous proteins. A model displaying the 
cross-sectional view of immune complexes is shown in Fig. 3-15c to illustrate the 
possible configurations of antibody binding to DENV. 
The above results demonstrated that 100µg/ml of h3H5 formed complexes with an 
average of 3 dengue virions in diameter, which could be translated to a lattice 
consisting of 27 virions in a 3-dimensional structure. These larger complexes may 
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 Figure 3-15 Immune complex size analysis by sucrose gradient and dynamic light 
scattering (DLS) 
 
Equal amounts of purified DENV were allowed to complex with 3µg/ml, 100µg/ml, 
33.3µg/ml h3H5 Fab or no antibody (virus control) for 1hr at 37°C. The immune 
complexes were then loaded onto a linearized 10-60% sucrose gradient and spun 
overnight at 4°C. Fractions were collected from bottom of tube and analyzed for (a) 
viral RNA copy number per fraction, where each point is the mean of 3 independent 
experiments and error bars indicate the SEM, and (b) DLS for complex size. The size 
distribution of complexes in the corresponding peak fractions were shown as 
diameters in nanometers (d.nm). The proposed cross-sectional view of complexes 



















4.1. Fluorescence labelling of DENV 
The early events of DENV infection in monocytes are not well understood and this has 
led to long delays in the development of a safe and effective tetravalent dengue vaccine. 
To improve this knowledge, we sought to visualize these interactions using fluorescently 
labelled virus and cells. The first part of this study was focused on the development of a 
DENV labelling method for AF594SE dye and characterizing the labelled virus to ensure 
that the attached fluorophores did not impair the infectivity of the virus. An optimized 
procedure for Alexa Fluor labelling of DENV was published [Zhang et al., 2010].  
However, it should be noted that Alexa Fluor conjugation to DENV increased the binding 
affinity of h4G2 antibody, but not h3H5, to the virions. The binding epitope of 3H5 had 
been mapped to amino acids 386 to 397 (QLKLNWFKKGSS) of the DENV E protein 
[Trirawatanapong et al., 1992], which consist of 3 lysine residues (K), where the amine-
reactive dye could potentially conjugate to. As the amine conjugation reaction is a 
random event, the fluorophores should not target these lysine residues on all the E 
proteins such that the epitopes of 3H5 are fully obscured. Hence, 3H5 binding to the 
labelled virions was not affected. It is known that 4G2 binds to a conformational epitope 
near the fusion loop, between amino acids 1-120 and 142-158 [Dejnirattisai et al., 2010], 
but the precise amino acids that make up the epitope have not been mapped. There are 
many arginine and lysine residues within these sequences, where the Alexa Fluor dye can 
react to. It is not understood why 4G2 binds to the labelled virus with higher affinity, but 
it can be speculated that the conjugation of the dye might have made the epitopes more 




Notwithstanding these limitations, the Alexa Fluor labelled virions would serve as a very 
useful tool for visualizing the early events of DENV complexes with monocytes. 
4.2. Cellular fate of DENV immune complexes in monocytes 
To identify the difference in the cellular fate of DENV complexes formed with either a 
homotypic or heterotypic antibody in monocytes, two human-mouse chimeric antibodies, 
h3H5 (homotypic) and h4G2 (heterotypic), were used. The visualization was first 
demonstrated in THP-1 cells and then verified with primary monocytes.  
Our observations suggested that the DENV immune complexes formed by the two 
antibodies interact with monocytes differently. With h3H5 at 3µg/ml, almost all the 
DENV complexes were rapidly internalized and co-localized to the late 
endosomes/lysosomes within 30min, whereas DENV complexes formed with 100µg/ml 
h4G2 stayed on the surface of cells and no sub-cellular trafficking was observed at this 
time point. This phenomenon might be the result of differential ability of the complexes 
to trigger Fc receptor-mediated phagocytosis. DENV complexes formed with 3µg/ml 
h3H5 interacted with both FcγRI and FcγRII on the surface of cells but internalized 
primarily through FcγRI at 30min time point. FcγRI is an activatory receptor. This 
suggests that complexes formed at this concentration of h3H5 can activate Fc receptor-
mediated phagocytosis and presumably leads to rapid transport to the late 
endosome/lysosomes for degradation of the cargo and thus stops productive infection of 
DENV. On the other hand, DENV complexes formed with 100µg/ml h4G2 were able to 
cluster both FcγRs on the surface of cells but unable to internalize at the 30min time 
point. When the complexes were finally internalized to late endosomes/lysosomes at the 
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2hr time point, there were no preferential engagement of Fc receptor as the complexes 
co-localized equally well to both FcγRI and FcγRII intracellularly. This suggests that the 
attachment of DENV complexes formed with h4G2 had an inhibitory effect on 
phagocytosis and this effect is only lifted after more than an hour of association with the 
monocytes.  
These observations suggest that the specific interaction of the complexes with monocytes 
is dependent on the antibody-antigen ratios used. Indeed, the association of large 
complexes with transient phagocytic defect in macrophages have been previously 
reported in in vivo observations for both influenza and dengue [Astry and Jakab, 1984; 
Chaturvedi et al., 1983], although a mechanistic explanation was not given for the 
reported observations. This thesis explored the possibility that high concentration of 
antibody aggregates viruses and thus forms immune complexes of a larger size. 
4.3. Antibody concentrations and complex size 
Immune complexes are the outcome of interactions of multivalent macromolecular 
antigens, such as whole virions, with bivalent or pentavalent antibodies [Mannik, 1980]. 
Antibody concentrations in proportion to antigens affect the size of immune complexes 
formed, which in turn influence the type and number of receptors they engage, and 
subsequent pathways activated. A probable explanation for our observations above is that 
with increasing antibody concentrations, the sizes of antibody-DENV complexes formed 
increase correspondingly, and at 100g/ml of the antibody, the complexes are large enough 
to interact with receptors that are normally expressed in lower density. As such, we next 
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questioned whether immune complex sizes might dictate the mechanism of DENV 
neutralization by antibodies. 
Sucrose gradient was used to separate the immune complex sizes formed by high 
(100µg/ml) and low (3µg/ml) concentrations of h3H5 IgG antibody. Both concentrations 
of h3H5 formed heterogeneous populations of immune complex sizes. However, analysis 
of complex sizes using DLS at their respective peak fractions indicated that h3H5 
at100µg/ml tends to form larger immune complexes (average diameter = 192nm) with 
DENV than at 3µg/ml (average diameter = 64.5nm), thus suggesting the antibody cross-
link the virions at the higher concentration.  
4.4. Conclusions 
This thesis demonstrated that antibody concentrations have a direct impact on the size of 
DENV immune complexes formed and their fates in monocytes. Higher antibody 
concentration results in larger complexes that can associate with Fc receptors but were 
inhibited from entry, whereas smaller complexes formed at lower antibody concentration 
enter the monocytes through FcγRI. One possible explanation for the inhibition of entry 
is the engagement of inhibitory Fc receptor. FcγRIIB is the only inhibitory Fc receptor. It 
is a low affinity Fc gamma receptor that constitutively expresses immunoreceptor 
tyrosine-based inhibitory motif (ITIM) in its cytoplasmic tail, normally present in much 
lower density than activatory receptors on monocytes. Hence it is more likely to be cross-
linked and activated by large immune complexes. It is therefore postulated that 
neutralization of DENV at high antibody concentrations engages FcγRIIB, which thus 
inhibit internalization of the complex. 
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However, as the staining antibody used does not differentiate between the isoforms of 
FcγRII, it was not possible to ascertain this. Nonetheless, a PhD student in our laboratory 
is testing this hypothesis using biochemical approaches. Indeed, preliminary results 
showed that knock down of FcγRIIB in THP-1 cells using specific siRNA significantly 
increased uptake of complexes at high concentration of h3H5, compared to the non-
specific siRNA control; and conversely, over-expression of FcγRIIB significantly 
reduced uptake of the complexes compared to mock transfected controls [Chan Kuan 
Rong, personal communication]. 
These differential Fc receptor interactions led to discernable phenotypes in monocytes, 
which could be used as a tool to distinguish between neutralization of homologous and 
heterologous DENV serotypes. 
4.5. Future work 
From our data above, we propose that homotypic antibodies is able to neutralize DENV 
at concentrations suitable for opsoniziation and directing of the complexes to late 
endosomes/lysosomes for degradation while cross-reactive antibodies can only neutralize 
DENV at a concentration that cross-links FcγRIIB where opsonization is inhibited. It is 
tempting to speculate that cross reactive antibodies cannot neutralize DENV 
intracellularly although more work will be needed to test this. However, this mechanism 
is proposed largely based on study with the two mouse mabs. Although a small panel of 
primary and secondary patient sera have been tested to showed similar observations 
[Chan et al., manuscript in submission], further assessment needs to be done with larger 
sample of well-characterized patients’ sera to confirm such a phenomenon. There is also 
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the possibility in the adaptation of our observations into an assay for screening vaccinees’ 
sera for presence of protective homotypic or more cross-reactive/less protective 
heterotypic antibodies. If successful, this assay would be very valuable in production and 
fine-tuning of dengue vaccines.  
Our results also gave a preliminary insight to the correlation between immune complex 
sizes and the proportion of activatory/inhibitory Fc receptors expression on monocytes. 
The inhibitory receptor FcγRIIB counters cell activation and induces immune tolerance to 
self-antigens and prevention of autoimmune diseases [Ravetch and Bolland, 2001]. Its 
polymorphism or deficiency has been implicated with autoimmune diseases and their 
severity [Clynes et al., 1999; Radstake et al., 2006; Smith and Clatworthy, 2010; Su et al., 
2007]. It would therefore be interesting to understand the contribution of FcγRIIB gene 
polymorphism in dengue disease in the presence of other immune cells, such as B and T 
cells.  
In this thesis, we also suggested that neutralization of DENV by antibodies guides the 
complexes into late endosomes/lysosomes through Fc receptor-mediated phagocytosis. 
However, there are other routes whereby the virus can gain entry into the cells, e.g. 
clathrin-mediated endocytosis, caveolin-dependent endocytosis [DeTulleo and 
Kirchhausen, 1998; Pelkmans, 2005]. DENV complexes entry into monocytes can end up 
in different pathways and thus different outcomes of infection (neutralization or 
enhancement). However, DENV complexes entry into monocytes has been poorly 
characterized. This information would be beneficial in specifically targeting the DENV 
complexes to intended compartments by use of drugs to block undesired pathways such 
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that the DENV complexes, even at sub-neutralizing levels of antibodies, will be directed 
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1. Cell culture medium 
1.1.   To prepare fetal bovine serum (FBS) 
Heat-inactivate at 56°C for 30mins and aliquot into 50ml Falcon tubes. Store at -20°C till 
further use. 
 
1.2.   To prepare BHK-21 growth medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
50ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.3.   To prepare BHK-21 maintenance medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
10ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.4.   To prepare Vero growth medium, 500ml 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
50ml FBS 
Top up to 500ml with Medium-199 (Gibco) and filter-sterilize 
 
1.5.   To prepare Vero maintenance medium, 500ml 
155 
 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
10ml FBS 
Top up to 500ml with Medium-199 (Gibco) and filter-sterilize 
 
1.6.   To prepare THP-1 growth medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of HEPES (1M, Gibco) 
454µl of β-mercaptoethanol (55mM, Gibco) 
50ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.7.   To prepare THP-1 maintenance medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of HEPES (1M, Gibco) 
454µl of β-mercaptoethanol (55mM, Gibco) 
10ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
1.8.   To prepare Raji-DC SIGN growth medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
50ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.9.   To prepare Raji-DC SIGN maintenance medium, 500ml 
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5ml of L-glutamine (200nM, Gibco) 
10ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.10. To prepare primary monocytes growth medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
50ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.11. To prepare primary monocytes maintenance medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
10ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.12.  To prepare 0.5% BSA/PBS 




2. Alexa Fluor labelling buffers 
2.1.   Sodium bicarbonate buffer, pH 8.3 
Dissolve 0.84g of sodium bicarbonate powder in 50ml deionized water. Adjust pH, if 
necessary, to 8.3 and filter-sterilize. 
 
2.2.   1.5M Hydroxylamine, pH 8.5 
Dissolve 1.05g of hydroxylamine in 5ml deionized water. Adjust pH to 8.5 with 5M 
sodium hydroxide, top up to 10ml with deionized water and filter-sterilize. 
 
2.3.   HNE buffer, pH 7.4 
0.651g HEPES (Sigma) 
4.38g sodium chloride (Sigma) 
0.019g EDTA (Sigma) 
Top up with 500ml deionized water, adjust pH to 7.4 and filter-sterilize.  
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3. Plaque assay 
3.1.   0.8% methycellulose overlay 
A. 2X RPMI 
Dissolve RPMI-1640 powder (Gibco) in 500ml deionized water 
10ml sodium bicarbonate (7.5%, Gibco) 
5ml sodium pyruvate (100mM, Gibco) 
20ml FBS 
Filter-sterilize 
B. 1.6% carboxy-methyl cellulose (CMC) 
Dissolve 8g of CMC (Calbiochem) in deionized water 
Autoclave-sterilize at 121°C, 20min 
 
Add 1 part of 2X RPMI (A) to 1 part of 1.6% CMC (B) in 50ml Falcon tubes. Shake 
vigorously to mix. Store at 4°C. 
 
3.2.   0.5% crystal violet in 25% formaldehyde 
5g crystal violet (Sigma) 
676ml 37% Formaldehyde 




4. Buffers for Immuno-assays 
4.1.   FACS wash buffer 
10ml FBS  
Top up to 1L with 1XPBS 
 
4.2.   FACS perm solution (0.1% saponin) 
Dissolve 1g saponin (Sigma) in 1L of 1X PBS. 
 
4.3.  12% paraformaldehyde (pFA) 
Dissolve 12g of pFA (Sigma) in 90ml of deionized water. Adjust pH to 7.2 and top up to 
100ml with 1X PBS. Filter-sterilize and store in -80°C in aliquots. 
 
4.4.  3% pFA 
Thaw a vial of 12% pFA and dilute 1 in 4 with 1X PBS. 
 
4.5.  Confocal wash buffer 
Dissolve 1g saponin (Sigma) in 1L of 1X PBS. 
 
4.6.  Confocal perm buffer 
1g of saponin (Sigma) 
5g BSA (Sigma) 
Top up to 100ml with 1X PBS 
 
4.7.  ELISA coating buffer 
0.212g sodium carbonate (Sigma) 
0.252g sodium bicarbonate (Sigma) 
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Dissolve in 50ml deionized water, adjust pH to 9.66 and filter-sterilize. 
 
4.8.  ELISA wash buffer (PBST) 
Add 500µl of Tween-20 to 1L of 1X PBS. 
 
4.9.  ELISA blocking buffer (1%) 
Dissolve 0.5g skim milk in 50ml of 1X PBS. 
 
4.10. ELISA antibody diluents (0.5%) 





5. Sucrose gradient 
5.1.   10% sucrose in HNE buffer 
5g sucrose (Sigma) 
Top up to 50ml with HNE buffer and filter-sterilize. 
 
5.2.   20% sucrose in HNE buffer 
10g sucrose (Sigma) 
Top up to 50ml with HNE buffer and filter-sterilize. 
 
5.3.   30% sucrose in HNE buffer 
15g sucrose (Sigma) 
Top up to 50ml with HNE buffer and filter-sterilize. 
 
5.4.   40% sucrose in HNE buffer 
20g sucrose (Sigma) 
Top up to 50ml with HNE buffer and filter-sterilize. 
 
5.5.   50% sucrose in HNE buffer 
25g sucrose (Sigma) 
Top up to 50ml with HNE buffer and filter-sterilize. 
 
5.6.   60% sucrose in HNE buffer 
30g sucrose (Sigma) 
Top up to 50ml with HNE buffer and filter-sterilize. 
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a b s t r a c t
Dengue virus causes frequent and cyclical epidemics throughout the tropics, resulting in signiﬁcantmor-
bidity andmortality rates. There is neither a speciﬁc antiviral treatment nor a vaccine to prevent epidemic
transmission. The lack of a detailed understanding of the pathogenesis of the disease complicates these
efforts. The development ofmethods to probe the interaction between the virus and host cellswould thus
be useful. Direct ﬂuorescence labelling of virus would facilitate the visualization of the early events in
virus–cell interaction. This report describes a simplemethod of labelling of dengue viruswith Alexa Fluor
succinimidyl ester dye dissolved directly in the sodiumbicarbonate buffer that yielded highly viable virus
after labelling. Alexa Fluor dyes have superior photostability and are less pH-sensitive than the common
dyes, such as ﬂuorescein and rhodamine,making them ideal for studies on cellular uptake and endosomal
transport of the virus. The conjugation of Alexa Fluor dye did not affect the recognition of labelled dengue
virus by virus-speciﬁc antibody and its putative receptors in host cells. This method could have useful
applications in virological studies.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Dengue is a signiﬁcant disease globally. With rapid urbaniza-
tion, lack of vector control and increase in air travel, dengue has
become the most common and rapidly spreading arthropod-borne
viral disease (Gubler, 1998). An estimated 50–100 million dengue
infections occur annually, and more are at risk of being infected
with 2.5 billion people living in dengue endemic countries (WHO,
2007). Despite research efforts, however, there remains an incom-
plete understanding on the mechanism underlying pathogenesis,
which limits antiviral and vaccine development. Among these gaps
in knowledge are the speciﬁc cell-surface binding motifs and early
viral entryprocesses. Theavailabilityof tools tovisualize theseearly
events can accelerate this area of research.
Dengue virus (DENV) is an enveloped, positive strand RNA virus
that belongs to the family of Flaviviridae. Its structure consists of
an external icosahedral scaffold of 90 envelope glycoprotein (E)
dimers protecting the nucleocapsid shell, which contains the RNA
genome (Kuhnet al., 2002). Dengue virus surfacehas several identi-
cal protein subunits and can therefore be labelled at multiple sites
using an amine reactive dye; the resulting ﬂuorescence intensity
may be sufﬁcient to track the virus under a ﬂuorescence micro-
scope.
∗ Corresponding author at: Duke-NUS Graduate Medical School, 8 College Road,
169857 Singapore, Singapore. Tel.: +65 6516 8594; fax: +65 6221 2529.
E-mail address: engeong.ooi@duke-nus.edu.sg (E.E. Ooi).
A simple procedure of labelling dengue virus with a ﬂuores-
cent Alexa Fluor succinimidyl ester that results in minimal loss
of infectivity post-labelling is described. Alexa Fluor dye was cho-
sen as it has better photostability and signal intensity compared
to common ﬂuorophores such as ﬂuorescein isothiocyanate (FITC)
or cyanine 3 bihexanoic acid (Cy3). In addition, Alexa Fluor dyes
are stable at a lower pH compared to the common ﬂuorophores,
which could be useful for visualizing labelled viral particles as
they move through the acidic compartments of endosomes post-
infection. Furthermore, the permanence of covalent conjugation
of the ﬂuorophores to the surface proteins allows for storage of
batch-labelled virus at −80 ◦C, providing uniformity across multi-
ple experiments. It also opens up the possibility of performing live
cell imaging to compliment the ‘snapshot’ imaging of conventional
ﬂuorescence microscopy.
2. Materials and methods
2.1. Cells and antibody
All cells and hybridomas were obtained from The American
Type Culture Collection (ATCC, Manassas, VA), and all cell culture
media and supplements were purchased from Gibco (Invitrogen,
Singapore). Baby hamster kidney BHK-21 cells were maintained in
Roswell Park Memorial Institute 1640 medium (RPMI-1640), sup-
plemented with 10% fetal bovine serum, penicillin (100U/ml) and
streptomycin (100g/ml) at 37 ◦Cwith 5% CO2. African greenmon-
key kidney Vero cells were maintained in Medium-199 (M199)
0166-0934/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.jviromet.2010.04.001
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supplemented with 10% fetal bovine serum and 4mM l-glutamine
at 37 ◦C with 5% CO2. Mouse anti-dengue virus serotype 2 E pro-
tein monoclonal antibody hybridoma, 3H5 (ATCC: HB46), was
maintained in RPMI-1640 supplemented with 10% fetal bovine
serum. Dendritic cell-speciﬁc ICAM3-grabbing non-integrin (DC-
SIGN) transfected-Raji B cell line was a kind gift from Timothy H.
Burgess (Naval Medical Research Centre, US) and maintained in
RPMI medium supplemented with 10% fetal bovine serum. Alexa
Fluor 488 (AF488) anti-mouse IgG antibody was purchased from
Molecular Probes, Invitrogen and used at 1:100 dilution.
2.2. Virus culture and puriﬁcation
DENV serotype 2 (DENV-2) (ST) strain was ﬁrst isolated from a
clinical sample in the Singapore General Hospital using an Aedes
albopictus mosquito cell line C6/36 and subsequently propagated
in Vero cells. The culture supernatant was harvested when 75%
of the cells showed cytopathic effect and clariﬁed by centrifuga-
tion at 1000× g for 30min at 4 ◦C. Virus in the supernatant was
concentrated by centrifugation at 30,000× g for 2h at 4 ◦C. The pel-
let was resuspended in 5mM Hepes, 150mM NaCl, 0.1mM EDTA
(HNE buffer, pH 7.4) and puriﬁed further on a 30% sucrose cush-
ion by ultracentrifugation in a Beckman SW41Ti rotor at 80,000× g
for 15h at 4 ◦C. Puriﬁed virus was resuspended in HNE buffer and
stored in 100l aliquots at −80 ◦C. A limiting dilution plaque assay
wasperformedonBHKcell line todetermine theviral titre inplaque
forming units per millilitre (pfu/ml).
2.3. Plaque assay
Tenfold serial dilutions of virus were added to BHK-21 cells in
24 well plates and incubated for 1h at 37 ◦C, with gentle rock-
ing every 15min. The medium was then aspirated and replaced
with 0.8% methyl-cellulose in maintenance medium (RPMI-1640,
2% fetal bovine serum, penicillin and streptomycin). After 4 days at
37 ◦C, the cells were ﬁxedwith 25% formaldehyde and stainedwith
0.5% crystal violet. The plates were washed, dried and the plaque
forming units per ml (pfu/ml) calculated.
2.4. Virus labelling
For the initial experiment aimed at determining the opti-
mal concentration of dye needed to label DENV, Alexa Fluor
594 succinimidyl ester (AF594SE, Molecular Probes, Invitrogen)
was reconstituted in 0.2M sodium bicarbonate buffer, pH 8.3
(SBB) immediately before labelling, and added to approximately
3×107 pfu DENV diluted in SBB at ﬁnal concentrations of 10,
50,100, 200, 500 and 1000M of dye, while stirring gently. The
dye-virus mixture was incubated at room temperature for 1h
with gentle inversions every 15min. The labelling reaction was
stopped by adding freshly prepared 1.5M hydroxylamine, pH 8.5
(Sigma–Aldrich) and incubated at room temperature for 1h with
gentle inversions every 15min. LabelledDENVwas re-titrated after
labelling and tested for ﬂuorescence using immunoﬂuorescence
assay.
For subsequent AF594SE or AF488SE labelling involving larger
batches of virus, the same approachwas employed and the labelled
DENV was puriﬁed using Sephadex G-25 columns (Amersham, GE
Healthcare, Singapore) to remove the excess dye. The labelled virus
was stored in 100l aliquots at −80 ◦C, re-titrated and tested for
ﬂuorescence before use.
2.5. Immunoﬂuorescence assay
Equal volume of AF594-labelled DENVwas incubatedwith Vero
cells plated on coverslips for 10min at 37 ◦C, washed, ﬁxedwith 3%
paraformaldehyde (Sigma–Aldrich, Singapore) and permeabilized
with 0.1% saponin (Sigma–Aldrich, Singapore). The cells were then
incubated for 1h with undiluted centrifugation-clariﬁed super-
natant of 3H5 monoclonal antibody hybridoma culture, at room
temperature. The cellswerewashed three times inwashbuffer (PBS
containing 1mM calcium chloride, 1mM magnesium chloride and
0.1% saponin), followed by incubation with AF488 anti-mouse IgG
antibody for 45min at room temperature. Cells were then washed
three timeswith thewash buffer, rinsed oncewith deionizedwater
and mounted on glass slides with Mowiol 4-88 (Calbiochem, San
Diego, CA) with 2.5% Dabco (Sigma–Aldrich, Singapore). Cells were
visualized at 63× magniﬁcation using a Leica Microsystem TCS SP5
confocal microscope and merged images exported for processing.
Processing of the images involved adjustment of the contrast of the
images on awhole for clarity and exported in individual colours for
unmerged images using Adobe Photoshop CS3 version 10.
2.6. Flow cytometry determination of labelled DENV
Raji B cells transfected with DC-SIGN were counted, aliquoted,
centrifuged and resuspended in AF488-labelled DENV atmultiplic-
ity of infection (MOI) of 1 and incubated for 10min at 37 ◦C, then
ﬁxedwith 3% paraformaldehyde. The cells were thenwashed twice
with FACS buffer consisting of PBSwith 0.1% fetal bovine serumand
permeabilized with 0.1% saponin in PBS. Cells were stained subse-
quently for the presence of DENV using anti-E protein monoclonal
antibody, 3H5, and PE anti-mouse anti-IgG antibody before reading
on BD FACS Caliburmachine and analysedwith CellQuest software,
version 3.3 (Becton Dickinson).
2.7. Detection by SYBR green-based real-time PCR
Real-time detection of viral RNA was conducted as described
previously (Lai et al., 2007) using pan-dengue forward and reverse
primers with some modiﬁcations. Brieﬂy, RNA extraction was car-
ried out using QIAamp viral RNA mini kit for puriﬁed non-labelled
and AF594-labelled DENV (AF594-DENV), or RNeasy mini kit (both
fromQIAGEN, Hilden, Germany) for total RNA extraction from cells
according to themanufacturer’s instructions. Complementary DNA
was synthesized using SuperScript III First Strand Synthesis Sys-
tem (Invitrogen, Singapore) with random hexamers and according
to the manufacturer’s instructions. RNA copy number was then
determined by SYBR green-based real-time PCR on LightCycler 480
Real-Time PCR System (Roche Diagnostics, Penzberg, Germany).
2.8. Growth kinetics
Vero cells were seeded at 2×105 per well in 24 well plates and
incubated at 37 ◦C for 4h before infecting at aMOI of 0.1with either
puriﬁed DENV or AF594-DENV for 1h at 37 ◦C, with gentle rocking
every 15min. The cells were then washed twice with 1ml per well
PBS and replacedwithmaintenancemedium (M199 supplemented
with 2% FBS). Supernatant was harvested from wells and stored at
−80 ◦C for plaque assay, and cells were washed twice in PBS and
lysedwithRLTbufferprovided inRNeasymini kit at 0, 6, 8, 12, 24, 48
and 72h post-adsorption. The cell lysates were stored frozen until
all samples were collected and subsequently extracted according
to the kit’s protocol. Viral RNA was detected using real-time PCR.
2.9. Statistical analysis
Statistical analyses were performed using unpaired Student’s t
test (GraphpadPrism5.0). P value <0.05was considered signiﬁcant.
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3. Results
3.1. Infectivity of DENV post-labelling
DENV was re-titrated by plaque assay post-labelling with
AF594SE (Fig. 1a). The virus titre of DENV labelledwith 10–100M
of AF594SE dye showed approximately 15-fold reduction, and
DENV labelled with 500 and 200MAF594SE dye showed approx-
imately 26- to 29-fold reductions, respectively, compared to
equivalent number of non-labelled virus. DENV labelledwith 1mM
of AF594SE dye showed an 82-fold reduction.
3.2. Intensity of AF594 labelling
Equal volume of DENV labelled with various concentrations of
AF594SE dye was incubated with Vero cells seeded on coverslips,
ﬁxed in 3% paraformaldehyde and stainedwithmouse anti-Emon-
oclonal antibody, 3H5, and AF488 anti-mouse IgG antibody. The
coverslips were then mounted on glass slides and examined using
a confocal microscope.
Cells infectedwith DENV labelledwith 10M to 1mMAF594SE
dye showed decreased staining for E protein with concentration
of dye above 200M, indicating a reduction in virus infectivity
post-labelling with higher concentrations of dye (Fig. 1b). This was
consistent with the plaque assay results. DENV labelled with 10
and50Mofdye showednodiscernableAF594ﬂuorescence,while
DENV labelledwith 100 and 200MofAF594SE dye displayed high
AF594 ﬂuorescence which co-localized well with the E protein as
highlighted by the 3H5monoclonal antibody. Fluorescence for both
AF594 and E protein diminished with AF594SE dye concentrations
of 500M and 1mM.
3.3. Efﬁciency of Alexa Fluor dye labelling
DC-SIGN transfected-Raji B cells were infected with AF488-
labelled DENV at a MOI of 1, stained for the presence of E protein
using 3H5 monoclonal antibody and analysed by ﬂow cytometry.
Compared to the uninfected Raji B cells with DC-SIGN, approxi-
mately 81.4% of the cells following infection were positive for the
E protein. Of these cells, 58.4% were positive for both E protein
and AF488 (Fig. 2a), suggesting that approximately 71% of the viri-
ons were labelled with the Alexa Fluor dye. Similar conclusions
can be drawn from the Pearson’s correlation values obtained by
analysis of confocal microscopy images showing co-localization of
AF594-DENV with E protein (Fig. 2b).
3.4. Reproducibility of labelling
Three independent AF594SE labelling experiments were per-
formed with the same approximate starting titre of 2×108 pfu
of puriﬁed DENV using the same procedure as described in Sec-
tion 2. The titre post-labelling was then determined by plaque
assay. All three experiments showed three- to eightfold reduc-
tion in titre post-labelling and column puriﬁcation, from a mean
titre of 2.21×108 (SD=3.68×107) to 3.78×107 (SD=1.5×107). To
exclude the possibility that the reduction in titre post-labellingwas
due to a loss in infectivity of the virus, the ratio of RNA copy number
to plaque forming unit of DENV pre- and post-labelling was anal-
ysed (the same batch of puriﬁed virus was used). No signiﬁcant
difference in the viral RNA copy number to plaque forming unit
ratio was observed between pre- and post-labelled virus (Table 1,
P=0.9507), indicating that the fall in titre was not due to inactiva-
tion of the virions but rather due to loss during columnpuriﬁcation.
Fig. 1. Dengue virus viability post AF594 labelling. Puriﬁed dengue virus was
labelled with various concentrations of AF594SE dye for 1h at room temperature
(described in Section 2.4). The labelled virus was then re-titrated post-labelling by
plaque assay. Bar diagram shows average virus titre of four determinations, pre- and
post-labelling (a). Error bars indicate standard deviation. The labelled viruswas also
tested for ﬂuorescence intensity by immunoﬂuorescence assay (b). Vero cells seeded
on coverslips the day prior are infected with labelled DENV for 10min at 37 ◦C. The
cells were subsequently ﬁxed and labelled with anti-E antibody, and examined for
co-localization of E protein (green) and AF594 labelling (red). Fluorescent signals
are visualized under 63× magniﬁcation using Leica Microsystem TCS SP5 confo-
cal microscope. Scale bar is 10m. White arrows indicate areas of co-localization
(yellow when merged). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of the article.)
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Fig. 2. Efﬁciency of Alexa Fluor dye labelling as a function of percentage infected. Raji B cells transfectedwithDC-SIGNwere infected at aMOI of 1withAF488-DENV for 10min
at 37 ◦C, ﬁxed and stained for the presence of E protein. Fluorescence was then measured using BD FACS Calibur (a). Close to 100% of uninfected Raji B cells with DC-SIGN
were double negative for both Alexa Fluor and anti-E antibody signals, whereas approximately 81% of the infected cells stained positive for E protein, and approximately
71% of which are positive for Alexa Fluor ﬂuorescence, suggesting that approximately 71% of the virions were labelled with the dye. Confocal microscope analysis of Vero
cells infected with AF594-DENV (red) and stained for E protein (green) showed a mean Pearson’s correlation of 0.677±0.053 (mean± SD) (b), suggesting similar labelling
efﬁciency (yellow indicates co-localization). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of the article.)
3.5. Growth kinetics of labelled DENV
In order to ascertain further that labelling of the surface proteins
ofDENVdidnot interferewith infectivity andgrowthkinetics of the
virus, Vero cells were infected with either puriﬁed non-labelled or
AF594-DENV at a MOI of 0.1. Culture supernatant and cell lysates
were collected up to 72h and assayed for virus titre in supernatant
as well as viral RNA in the cell lysates. No signiﬁcant difference
was observed between labelled and unlabelled virus for both viral
RNA copy number and the number of infectious particles in the
supernatant of the culture (Fig. 3) (P>0.8).
Table 1
Viral RNA copy number to infectious particle ratio.




AF594-DENV 3.5×107 6.27×108 17.9
Puriﬁed DENV 1.0×109 1.67×1010 16.7
Viral RNAwas extracted from puriﬁed non-labelled DENV or AF594-DENV and RNA
copy number quantitated by real-time PCR. The RNA copy numberwas then divided
by the titre to obtain a ratio for both non-labelled DENV (16.7) and AF594-DENV
(17.9). The similar ratios indicated that both labelled and non-labelled DENV have
comparable infectious/non-infectious proportions, suggesting that the labelling
process did not inactivate the virions.
4. Discussion
Direct ﬂuorescent labelling of virus allows for real-time track-
ing of post-internalization events and requires few labelling steps,
removing the possibility of non-speciﬁc staining that could be
introduced with the use of indirect antiviral antibodies. The track-
ing of single-virus entry into cell by labelling DENV with lipophilic
DiD (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 4-
chorobenzenesulfonate salt) was described recently (van der
Schaar et al., 2007, 2008). However, as DiD ﬂuorescence is largely
quenched when the ﬂuorophores are in close proximity to each
other (e.g. on virion surface) and will only ﬂuoresce brightly fol-
lowing fusion with cellular membranes, the DiD-labelled virions
are not traceable easily prior to fusion. This hampers the visualiza-
tion of early virus–cell interaction. In addition, theDiDﬂuorescence
post-fusion tends to be diffused, possibly due to rapid lipid recy-
cling, thus complicating co-localization studies. Furthermore, the
labelling is not stable and labelled virus can only be stored in the
cold for up to 3 days. Hence, a ﬂuorophore, such as Alexa Fluor, that
is unquenched extracellularly and stably conjugates to the virus
surface proteins would enable the tracking of virus within a cell
rather than visualizing lipid movement.
Currently, there is no standardized procedure for ﬂuorescence
labelling of viruses and protein labelling protocols by manufac-
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Fig. 3. Comparing the growth kinetics of puriﬁed non-labelled and labelled DENV.
Vero cells were plated and allowed to adhere before infecting at a MOI of 0.1 with
eitherAF594-DENVornon-labelledDENV.Viral RNAcopynumber in cell lysateswas
determined to assess viral replication (a) and supernatantwas assayed for infectious
particles by plaque assay (b). There is no signiﬁcant difference between the growth
curves of labelled and non-labelled dengue virus in RNA copy number (P=0.8630)
and total pfu (P=0.8191). Each point is an average of four determinations.
turers often call for the use of dimethyl sufoxide (DMSO) to
reconstitute the dye. DMSO can block productive infection of
virus in cells, even when present in minute amounts, and may
induce cell cytotoxicity (Aguilar et al., 2002) which could affect
downstream assays. An alternative method of producing infective
labelled viruseswithout the use of DMSOwould therefore be desir-
able. This initiated the assessment of labelling of DENV with Alexa
Fluor succinimidyl ester dye dissolved directly in the sodiumbicar-
bonate buffer since the dye is highly soluble in aqueous solution.
The results obtained indicate that this approach is able to produce
viable labelled DENV that can be visualized easily by ﬂuorescence
microscopy. The ﬁndings were also reproducible and consistently
yielded ﬂuorescently labelled virus with less than tenfold drop in
titre following column puriﬁcation.
Alexa Fluor dyes are small molecules that react with free amino
groups, primarily arginine and lysine (Huang et al., 2004), usu-
ally outward-facing amino acids. Despite its relatively small size
compared to other ﬂuorescent proteins, increasing the concen-
tration of the dye used for labelling correlated with a reduced
viral titre. This was observed with concentrations of AF594SE dye
greater than 200M. An optimal level of labelling should thus
balance between the degree of labelling and the functional abro-
gation (Freistadt and Eberle, 2006). Consequently, although DENV
labelled with 200M of dye showed brighter ﬂuorescence over
100M of dye, 100M was chosen for subsequent experiments
as it provided adequate labelling with minimal loss of viability of
DENV.
The labelled DENV retained the ability to be recognized by anti-
E antibody and DC-SIGN expressed on transfected-Raji B cells as
demonstrated by immunoﬂuorescence assays performed on FACS
and confocal microscope. Raji B cells are not normally suscepti-
ble to DENV infection, but DC-SIGN transfection renders these cells
permissive to this virus (Martin et al., 2006; Tassaneetrithep et al.,
2003; Wu et al., 2004). This suggests that conjugation of the Alexa
Fluor dye molecules to the surface of DENV did not alter nor block
important epitopes of the surface glycoproteins used for receptor
recognition. Additional assays were also conducted to determine
whether labelling of the viral proteins would interfere with its
infection and replication in normally permissive cells. Study of the
growthkinetics inVero cells showedno signiﬁcant difference in the
infectivity or replication rate between the labelled and the non-
labelled virus as indicated by the viral RNA copy number in cells
and titre in the supernatant (P>0.8).
To estimate the percentage of virus labelled with the ﬂuores-
cence dye using this method, ﬂow cytometric studies were carried
out using DENV labelled with AF488SE dye. Approximately 58.4%
of the cell population were positive for both AF488 and anti-E
staining, out of a total of 81.4% infected. This suggests that approx-
imately 71.7% of the virus preparation was actually labelled with
AF488 dye. Although AF594-DENV could not be assessed for efﬁ-
ciency of labelling on the ﬂow cytometer used, due to the lack of
appropriate excitation laser, Pearson’s correlation values obtained
from co-localization studies using confocal microscopy revealed
that similar labelling efﬁciency can be achieved.
Even though it has not been demonstrated in this report, this
approach of labelling DENV should apply to the other serotypes. As
the labelling chemistry is the same, different ﬂuorophores can also
be used (AF594 and AF488 demonstrated here). This could increase
the range of applications of the labelled virus (e.g. ﬂow cytometry,
confocal microscopy). In addition, conjugation of dye to viral pro-
teins is stable and the labelled virus could be stored frozen until
use. Experience in this laboratory indicates that labelled virus can
be stored at −80 ◦C for up to 8 months without noticeable loss in
ﬂuorescenceor viral titre. Thus, a largebatchof virus canbe labelled
andused for consecutive experiments tominimize inter-assay vari-
ations.
In conclusion, Alexa Fluor labelled virus provides a useful
method for tracking the early events in virus–cell interaction.
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Short Abstract:  
Taking advantage of the advancements in fluorophore development and imaging technology, a 
simple method of Alexa Fluor labeling of dengue virus was devised to visualize the early 
interactions between virus and cell. 
Long Abstract:  
The early events in the interaction between virus and cell can have profound influence on the 
outcome of infection. Determining the factors that influence this interaction could lead to 
improved understanding of disease pathogenesis and thus influence vaccine or therapeutic 
design. Hence, the development of methods to probe this interaction would be useful. Recent 
advancements in fluorophores development1-3 and imaging technology4 can be exploited to 
improve our current knowledge on dengue pathogenesis and thus pave the way to reduce the 
millions of dengue infections occurring annually. 
The enveloped dengue virus has an external scaffold consisting of 90 envelope glycoprotein (E) 
dimers protecting the nucleocapsid shell, which contains a single positive strand RNA genome5. 
The identical protein subunits on the virus surface can thus be labeled with an amine reactive dye 
and visualized through immunofluorescent microscopy. Here, we present a simple method of 
labeling of dengue virus with Alexa Fluor succinimidyl ester dye dissolved directly in a sodium 
bicarbonate buffer that yielded highly viable virus after labeling. There is no standardized 
procedure for the labeling of live virus and existing manufacturer’s protocol for protein labeling 
usually requires the reconstitution of dye in dimethyl sulfoxide. The presence of dimethyl 
sulfoxide, even in minute quantities, can block productive infection of virus and also induce cell 
cytotoxicity6.  The exclusion of the use of dimethyl sulfoxide in this protocol thus reduced this 
possibility. Alexa Fluor dyes have superior photostability and are less pH-sensitive than the 
common dyes, such as fluorescein and rhodamine2, making them ideal for studies on cellular 
uptake and endosomal transport of the virus. The conjugation of Alexa Fluor dye did not affect 
the recognition of labeled dengue virus by virus-specific antibody and its putative receptors in 
host cells7. This method could have useful applications in virological studies. 
Protocol Text:  
1.) Alexa Fluor labeling of dengue virus 
1.1) Before the labeling reaction, purify dengue virus with sucrose cushion and prepare the 
necessary reagents and equipment as indicated in the protocol. 
1.2) Prepare fresh 0.2M sodium bicarbonate buffer, pH 8.5 (labeling buffer), and 1.5M 
hydroxylamine buffer, pH 8.3 (stop reagent), just before labeling and filter sterilize with 0.2µm 
syringe filters. 
1.3) Dilute approximately 3x108 plaque forming units (pfu) of purified dengue virus in 1ml of 
labeling buffer in a 2ml tube. This can be scaled up proportionally for batch labeling of virus. 
1.4) Reconstitute the lyophilized Alexa Fluor 594 (AF594) succinimidyl esters to 1mM in 
labeling buffer immediately prior to the labeling reaction. Other fluorochromes from the Alexa 
Fluor dye series may be used according to one’s needs. Minimize exposure to light from this step 
onwards. 
1.5) Add 100µl of the 1mM AF594 dye to the diluted virus while stirring gently with the pipette 
tip. 
1.6) Incubate the labeling reaction mix at room temperature for 1hr in the dark. Mix by gentle 
inversions every 15mins. 
1.7) Spin the tube briefly in a tabletop centrifuge and add 100µl of stop reagent to the reaction 
mix while stirring gently with the pipette tip.  
1.8) Incubate at room temperature for an additional hour in the dark. Mix by gentle inversions 
every 15mins. 
2.) Purifying Alexa Fluor labeled dengue virus 
2.1) In the meantime, equilibrate the purification column with buffer of choice. In this 
experiment, a PD-10 column is equilibrated with 25ml of HNE buffer (5mM Hepes, 150mM 
NaCl, 0.1mM EDTA), pH 7.4, before use. 
2.2) Apply the labeled virus to the top of the column and start collecting the flow-through once 
the labeled virus enters the matrix. Fill the column with HNE buffer once all the labeled virus 
has entered the matrix. Discard the first 2.5ml of flow-through and collect the next 2ml of 
labeled virus fraction. 
2.3) Aliquot and store purified AF594 labeled dengue virus in -80°C, away from light source. 
3.) Checking virus viability and fluorescence 
3.1) Thaw one aliquot and determine the titer of the labeled virus by plaque assay before using 
the batch of labeled virus. 
3.2) Seed 5x104 per well of Vero cells, grown in M-199 growth medium, in a 4-well plate with a 
coverslip on the bottom of well a day before infection. 
3.3) Remove the culture supernatant in well and infect the cells with multiplicity of infection of 1 
of the labeled virus in 100µl volume (diluted in M-199 maintenance medium as required) for 
10min at 37°C. 
3.4) Remove the inoculums and wash the coverslips twice in 1xPBS. 
3.5) Fix the cells in 3% paraformalydehyde for 30mins. 
3.6) Wash the coverslips 3 times in 1xPBS. 
3.7) Permeabilize the cells with permeabilization solution containing 0.1% saponin and 5% BSA 
in 1xPBS for 30mins. 
3.8) Incubate the cells with undiluted centrifugation-clarified supernatant of 3H5 monoclonal 
antibody hybridoma culture for 1hr in a humid chamber, protected from light. 
3.9) Wash the coverslips 3 times in wash buffer (1xPBS containing 1mM calcium chloride, 1mM 
magnesium chloride and 0.1% saponin). 
3.10) Incubate the cells with AF488 anti-mouse IgG antibody, 1:100 diluted in permeabilization 
solution, for 45mins in humid chamber, protected from light. 
3.11) Wash the coverslips 3 times in wash buffer and rinse once in deionized water. 
3.12) Dab the edge of coverslip against a paper towel to drain excess water and mount on to 
glass slide with 8μl Mowiol 4-88 containing 2.5% Dabco. 
3.13) Allow the mounting solution to set overnight at 4°C before viewing using a Zeiss confocal 
microscope. Sequential acquisitions should be performed exciting one fluorophore at a time and 
switching between the detectors concomitantly. 
3.14) Images are then analyzed for co-localization of the E protein antibody staining with the 
labeled virus using the Zeiss LSM Zen software to estimate the degree of labeling. 
 
Representative Results:  
An example of the yield of dengue virus labeled with AF594 dye is shown in Figure 2. 
Normally, less than 10-fold drop from the initial titer should be observed following successful 
labeling. However, it should be noted that all buffers have to be prepared fresh for the labeling to 
be successful and the Alexa Fluor succinimidyl esters should be used immediately upon 
reconstitution as they hydrolyze into nonreactive free acids in aqueous solutions8. 
Next, the labeled virus has to be checked for sufficient fluorescence before use in experiments. A 
simple immunofluorescence assay was done on Vero cells and the degree of labeling can be 
estimated from the co-localization of the labeled virus with anti-E protein antibody staining. 
Several cells were examined and a typical confocal image is shown in Figure 3. Co-localization 
analysis of the images using the LSM Zen software demonstrated overlap coefficients ranging 
from 0.65 to 0.8, suggesting that approximately 65 to 80% of the virions were labeled with the 
dye. 
 
Tables and Figures (Required):  
Figure 1: Overall scheme depicting the Alexa Fluor dye labeling of dengue virus procedure. 
First, the relevant buffers and purified dengue virus are prepared. The Alexa Fluor dye is 
reconstituted and added to the dengue virus diluted in labeling buffer. The reaction is then 
stopped 1 hour later with the addition of stop reagent. Subsequently, the labeled virus is purified 
through a size exclusion column to remove free dye. Finally, the labeled virus is re-titrated by 
plaque assay and tested for fluorescence. 
Figure 2: Mean number of viable virions (pfu/ml) as determined on a plaque assay before 
and after AF594 labeling. An aliquot of the AF594 labeled dengue virus is thawed and re-
titrated by plaque assay and it typically shows less than 10-fold drop from the starting titer. Error 
bars indicate standard deviation of duplicates. 
Figure 3: Co-localization of AF594 labels with dengue virus E proteins in Vero cells. Vero 
cells grown on coverslips the day prior were infected with AF594 labeled dengue at MOI of 1 for 
10 minutes at 37°C. The cells were subsequently fixed and labeled with anti-E antibody, and 
examined for colocalization of E protein (green) and AF594 labeling (red). Fluorescent signals 
were visualized under 63X magnification using Zeiss LSM 710 confocal microscope. Scale bar 
is 10µm. Yellow indicate areas of colocalization, as shown in the inset. 
 
Discussion:  
Although AF594 dye was used in this report, a wide range of fluorophores in the Alexa Fluor 
succinimidyl esters series is available with similar labeling chemistry. This could extend the 
labeling application beyond imaging. Flow cytometry can be used as an alternative to confocal 
microscopy for estimating the degree of labeling for fluorophores that can be excited and 
detected by the FACS machine.   
Alexa Fluor dyes are small molecules that react with free amino groups, primarily arginine and 
lysine9, normally outward facing residues of proteins. In our laboratory, conjugation of dengue 
virus with 100μM of Alexa Fluor 594 dye provided sufficient brightness for imaging with 
minimal loss in the viral titer. Different brightness may be achieved by varying the concentration 
of dye used. However, increasing the dye concentration can reduce virus viability7,10. One 
possible limitation is the interference in receptor binding due to the blockade of access by the 
fluorophores. Therefore, depending on application, an optimal level of labeling should be 
determined to ensure a balance between the degree of labeling and functional abrogation10. Do 
note that the concentration can also be affected by the post-packaging reactivity of the Alexa 
Fluor succinimidyl esters8.  
The direct labeling of dengue virus with Alexa Fluor dye presented here does not require any 
additional labeling steps to visualize the virus, thus removing the possibility of non-specific 
staining from indirect antiviral antibodies. It also allows for real-time tracking of post-
internalization events in live cell imaging. This method is relatively simple, and because the 
conjugation is stable, it can be used to produce and store batch-labeled virus for multiple 
experiments as opposed to lipophillic fluorescent dyes, such as long-chain carbocyanine1,1-
dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine (DiD) or styryl dyes, which cannot be stored 
in the cold for more than 3 days. 
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Table of specific reagents and equipment: 
Name of the reagent Company Catalogue number Comments (optional) 
Sodium bicarbonate Sigma-Aldrich S6297   
Hydroxylamine Sigma-Aldrich 159417  






PD-10 column GE Healthcare 17-0851-01  
Hepes Sigma-Aldrich H6147  
NaCl Sigma-Aldrich S3014  
EDTA Sigma-Aldrich E9884  
M-199 Invitrogen 11150  
FBS Hyclone SH30070.03  
4-well plate Nunc 176740  
Coverslips Einst 0111520  
Microscope slide Sail Brand 7105  
3H5 hybridoma ATCC HB46  
10x PBS 1st Base BUF-2040-10X1L  
Saponin Sigma-Aldrich S4521  
BSA Sigma-Aldrich A7906  
Magnesium chloride Sigma-Aldrich M2670  
Calcium chloride Sigma-Aldrich C3306  
Paraformaldehye Sigma-Aldrich 15,812-7  
Mowiol 4-88 Calbiochem 475904  
Dabco Sigma-Aldrich D27802  
Tabletop centrifuge Eppendorf 5424  
Confocal microscope Zeiss LSM 710  
  
To prepare M-199 growth medium, add 50ml of FBS, 5ml of sodium pyruvate and 5ml of non-
essential amino acids to 500ml of M-199, sterile filter.  
 
To prepare M-199 maintenance medium, add 15ml of FBS, 5ml of sodium pyruvate and 5ml of 
non-essential amino acids to 500ml of M-199, sterile filter. 
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